Sodium fluoride and potassium nitrate
208166
Clinical Protocol 08 Aug 2017
Property  of GSK Consumer Healthcare
Confidential
May not be used, divulged, published or otherwise disclosed
without the consent of GSK
Template Version Effective: 22 -Jun-2017CLINICAL PROTOCOL
ARANDOMIZED, EXAMINER BLIND, CROSSOVER, IN SITU EROSION STUDY TO 
INVESTIGA TE THE EFFICA CYOF AN EXPERIMENT AL DENTIFRICE IN 
REMINERA LIZA TION OF PREVIOUSLY SOFTEN EDENAM ELCOMPA RED TO A  
PLACEBO DENTIFRICE
Compound Name:  Sodium  fluoride and potassium nitrate
United States (US) Investigational 
New Drug (IND) Number:N/A
European Clinical Trials Database 
(EudraCT) Number:N/A
Other Regulatory Agency Identified
Number:N/A
Protocol Number:208166
Phase:III
Page 1 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 1 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Sponsor information
Sponsor Legal Registered Address GlaxoSmithKline Research & Development 
Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Sponsor Contact Address GlaxoSmithKline Consumer Healthcare (GSK CH)
GlaxoSmithKline Consumer Healthcare Holdings 
(US)
LLC
184 Liberty Corner Rd., Warren, NJ 07059 United 
States
Tel: 
Page 2 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 2 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Document History
Document Version Date Summary of Changes 
Original protocol 08/08/2017 Not applicable (N/A)
Amendments incorporate all revisio ns to date, including amendments made at the request of 
country  heal th authori ties, institutional review boards/ethi cs commi ttees (IRBs/ECs), etc.  
Page 3 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 3 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017PRINCIPAL INVESTIGATOR PROTOCOL A GREEMENT PAGE
I confirm agreement to conduct the study  in compliance wit h the protocol and any 
amendments and according to the current ICH GCP guidelines.
I acknowl edge that I am responsible for overall study  conduct. I agree to personally 
conduct or supervise the descri bed study .
I agree to ensure that all associates, colleagues and emplo yees assist ing in the conduct of 
the study  are inform ed about thei r obligat ions. Mechanisms are in place to ensure site staff 
receives all appropriate informat ion throughout the study .
I agree to conduct this study  in full conformance wit h the l aws and regulations of the 
country  in which the research is conducted and the Declarat ion of Helsinki.
Invest igator Name: Dr. Anderson Hara 
Invest igator Qualificat ions: DDS, MS, PhD
Invest igator Signature:
Date of Si gnature/ Agreement:
DD/MMM/YYYY
Page 4 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 4 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Table of contents
Sponsor information ........................................................................................................ 2
Docum ent Hi story........................................................................................................... 3
PRINCIPAL INVESTIGATOR PROTOCOL AGREEMENT PAGE .............................. 4
Table of contents ............................................................................................................. 5
List of tables ................................................................................................................... 9
SCHEDULE OF ACTIVITIES ..................................................................................... 10
1INTRODUCTION ........................................................................................................ 12
1.1 Mechanism of Act ion/Indicat ion........................................................................ 13
1.2 Background and Rat ionale................................................................................. 13
2STUDY OBJECTIVES AND ENDPOINTS ................................................................. 15
3STUDY DESIGN AND SUBEJCT POPULATION ...................................................... 16
4SUBJECT SELECTION ............................................................................................... 18
4.1 Inclusio n Cri teria............................................................................................... 18
4.2 Exclusio n Cri teria.............................................................................................. 19
4.3 Randomization Criteria ...................................................................................... 19
4.4 Lifest yle Guidelines ........................................................................................... 19
4.4.1 Meals and Dietary  Restri ctions.......................................................... 20
4.5 Screen Failures .................................................................................................. 20
4.6 Sponsor’s Qualified Medical Personnel .............................................................. 21
5STUDY TREATMENTS .............................................................................................. 21
5.1 Blinding and Allocat ion to Treatm ent/Rando mizat ion........................................ 21
5.2 Breaking the Blind ............................................................................................. 22
5.3 Subject Com pliance ........................................................................................... 23
5.4 Invest igational Product Supplies ........................................................................ 23
5.4.1 Dosage Form and Packaging .............................................................. 24
5.4.2 Preparati on and Dispensing ................................................................ 25
5.5 Administrati on................................................................................................... 25
5.5.1 Medicat ion Errors .............................................................................. 25
5.6 Invest igational Product Storage .......................................................................... 26
5.7 Invest igational Product Accountabilit y............................................................... 26
5.7.1 Destruction of Invest igational Product Supplies ................................
. 27
5.8 Concomitant Treatment(s) ................................................................................. 27
6STUDY PROCEDURES ............................................................................................... 27
Page 5 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 5 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20176.1 Visit 1 –Screening ............................................................................................. 27
6.2 Study  Period...................................................................................................... 29
6.2.1 Visit 2 –Period 1 ............................................................................... 29
6.2.2 Visit 3 –Period 2 ............................................................................... 31
6.2.3 Visit 4 –Period 3 ............................................................................... 32
6.3 Subject Withdrawal ............................................................................................ 34
7ASSESSMENTS ........................................................................................................... 36
7.1 Efficacy ............................................................................................................. 36
7.2 Safety................................................................................................................ 36
7.3 Laboratory  Procedures ....................................................................................... 37
7.4 Salivary  flow..................................................................................................... 38
8ADVERSE EVENT AND OTHER EVENTS OF SPECIAL INTEREST 
REPORTING ................................................................................................................ 39
8.1 Definit ions of Adverse Events and Serious Adverse Events ............................... 39
8.1.1 Adverse Event ................................................................................... 39
8.1.2 Serious Adverse Event ....................................................................... 40
8.2 Reporting Period ................................................................................................ 41
8.2.1 Adverse Event ................................................................................... 41
8.2.2 Serious Adverse Event ....................................................................... 41
8.3 Reporting Procedures ......................................................................................... 41
8.3.1 Adverse Event ................................................................................... 42
8.3.2 Serious Adverse Event ....................................................................... 42
8.3.3 Sponsor’s Reporting Requirements to Regulatory  Authori ties and 
Ethics Co mmit tees............................................................................. 43
8.4 Evaluat ing Adverse Events and Serious Adverse Events .................................... 44
8.4.1 Severit y Assessment .......................................................................... 44
8.4.2 Causalit y Assessment ......................................................................... 44
8.5 Withdrawal Due to an Adverse Event and Serious Adverse Events .................... 45
8.6 Pregnancy .......................................................................................................... 45
8.6.1 Time Period for Collect ing Pregnancy Informat ion............................ 45
8.6.2 Action to be Taken if Pregnancy Occurs ............................................ 45
8.7 Follow-up of  Adverse Events and Serious Adver se Events ................................. 46
8.8 Definit ion of and Procedure for Reporting Medical Device Incidents ................. 46
8.8.1 Definit ion of an Incident .................................................................... 46
8.8.2 Reporting of an Incidents and Malfunct ions....................................... 47
Page 6 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 6 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20178.8.3 Follow-up of  Medical Device Incidents .............................................. 48
8.8.4 Regulatory  and Ethi cs Reporting Requirements for Inci dents ............. 48
9DAT A MANAGEMENT .............................................................................................. 49
9.1 Source Documents/ Data .................................................................................... 49
9.2 Case Report Form .............................................................................................. 49
9.3 Data Handling .................................................................................................... 50
9.3.1 Queri es.............................................................................................. 50
9.4 Processing Patient Reported Outcomes .............................................................. 50
9.5 External Data ..................................................................................................... 51
10STATISTICAL CONSIDERATIONS AND DATA ANALYSES ................................. 51
10.1 Sample Si ze Determinat ion................................................................................ 52
10.2 Statistical Methods and Analyt ical Plan ............................................................. 52
10.2.1 Dem ographic and Baseline Characteristics ......................................... 52
10.2.2 Primary Analysis(es) .......................................................................... 53
10.2.3 Secondary  Analysis(es) ...................................................................... 53
10.2.4 Safety Analysis(es) ............................................................................ 54
10.2.5 Other Analysis(es) ............................................................................. 55
10.2.6 Definit ion of Analysis Populat ions..................................................... 56
10.2.7 Exclusio n of Data fro m Analysis ........................................................ 56
10.2.8 Handling of Dropouts and Missing Data ............................................ 57
10.2.9 Interim Analysis ................................................................................ 57
11STUDY GOVERNANCE CONSIDERATIONS ........................................................... 57
11.1 Qualit y Control .................................................................................................. 57
11.2 Qualit y Assurance .............................................................................................. 58
11.3 Regulatory  and Ethi cal Considerat ions............................................................... 58
11.3.1 Institutional Review Board/ Ethi cs Committee ................................... 58
11.3.2 Ethical Conduct of the Study.............................................................. 58
11.3.3 Subject Informat ion and Consent ....................................................... 59
11.3.4 Subject Recruitment ........................................................................... 59
11.3.5 Reporting of Safet y Issues and Seri ous Breaches of the Protocol or 
ICH GCP ........................................................................................... 59
11.4 Posting of Information on Publicly Available Clinical Trial Registers ................ 60
11.5 Provisio n of S tudy Result s to Invest igators ........................................................ 60
11.6 Records Retention .............................................................................................. 60
Page 7 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 7 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-201711.7 Condi tions for Terminat ing the Study ................................................................ 61
11.8 Definit ion of Study  End/ End of Study ............................................................... 62
12REFERENCES ............................................................................................................. 62
13APPENDIX .................................................................................................................. 63
13.1 ABBREVIATION ............................................................................................. 64
Page 8 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 8 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017List of tables
Table 1-1 Schedule of Act ivities........................................................................ 10
Table 2-1 Study  Objectives and Endpoints ......................................................... 15
Table 13-1 Abbreviat ion...................................................................................... 64
Page 9 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 9 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017SCHEDULE OF ACTIVITIES
The schedule of act ivities table provides an overview of the protocol visits and procedures.  
The invest igator may schedule visits (unplanned visits) in addition to those listed on the 
schedule of activities, in order to conduct evaluatio ns or assessments requi red to protect the 
well-being of the subject.
Table 1-1 Schedule of A ctivities
Screening Study period
Procedure/ Assessment Period 1 Period 2 Period 3
Visit 1 Wash 
outVisit 2Wash 
outVisit 3Wash 
outVisit 4
Informed consent X
Minimum 3  days including a 2 days washout using a non fluoride toothpaste 
Minimum 3 days including a 2 days washout using a non fluoride toothpaste 
Minimum 3 days including a 2 days washout using a non fluoride toothpaste Demographics and ethnicity X
Medical h istory X
Prior medications X
Screening OHT assessment X
Screening OST assessment X
Unstimulated saliva flow rate X
Stimulated saliva flow rate X
Inclusion / Exclusion Criteria X
Subject Eligibility X
Try-in palatal appliance X
Dispense wash -out products X
Concomitant medication X X X
Continued eligibility  X X X
Diary cards review X X X
Pre-treatment OST 
assessmentX X X
Randomize to treatment X
Place enamel specimens in X X X
Page 10 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 10 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Abbreviations:  
OST: Oral soft tissue
OHT: Oral hard tissue 
Any serious adv erse ev ent assessed as related to study participation that occurs subsequent to the 
signing of informed consent and any adv erse ev ent that occurs subsequent to the screening visit will 
be recorded.
1. Laboratory analysis of enamel specimens performed prior to placing the specimens in intraoral appliance are specified in Section 7.3 
2. Four enamel specimens will be removed at 2 hours ± 10 min from palatal appliance for analysis .Laboratory analysis of enamel specimens 
described in Section 7. 3.  
3. Four enamel specimens will be removed at 4 hours (2 hours ± 10 min from previous time point) from palatal appliance for analysis .
Laboratory analysis of enamel specimens described in Section 7.3.  
4. At the end of the intraoral phase, and after allenamel specimens are removed, the appliance will be disinfected and stored at site until the 
next treatment visit.  palatal appliance1
Place palata l appliance in 
subject’s mouthX X X
Supervised Treatment X X X
Intra oral phase 2 hours 2X X X
Intra oral phase 4 hours 3, 4X X X
Post-treatment OST 
assessment X X X
Post-treatment OHT 
assessmentX
Collect wash -out products X
Adverse Events X X X X
Incidents X X X X
Study Conclusion X
Page 11 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 11 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20171 INTRODUCTION
Dental  erosion is the irreversible loss of tooth substance by chemical processes not 
involving bacteri a. It is a cycli cal process, influenced by demineralizat ion and 
remineralizat ion. Demineralizat ion of the enamel surface can occur by the exposure to acids 
either from internal origin, such as gastri c acids from  refluxes, and or external from dietary 
sources; if of suffic ient frequency and severi ty. The erosive challenges in vivo are brief and 
it’s unlikely they are a major cause of surface loss when occurring on their own (Shellis et al 
2011) , but this softening of the hard tissues surface makes it more suscept ible to further 
physical wear from abrasio n (tooth brushing) and attrit ion (grinding) resul ting in tissue loss. 
The process of demineralizat ion cycles with remineralizat ion, which is the process of placing 
minerals back into the previously demineralized hard tissue, ideally to achieve mineral that is
more resistant to subsequent demineralizat ion (Cochrane et al 2012) . 
It is well accepted that fluori de containing dent ifrices shoul d be part of  an appropri ate 
clinical management strategy  for the prevent ion of cari es (Brunelle and Carlos 1990) (Stephen 
1993) (Bartizek et al 2001) and to promote tooth remineralizat ion and r educe demineralizat ion 
(Featherstone et al 1990) (Chow 1990) . Fluoride can be administered in many different form s, 
most comm only sodium fluori de (NaF), sod ium monofluorophosphate (NaMFP) and stannous 
fluori de (SnF2) . However, besi des the fluori de form and concentrati on, there are other aspects 
of a dentifrice that have a strong influence in the uptake of fluoride as has been shown in in 
vitro and in situ invest igations (Barl ow et al  2009, Fowl er et al  2006, Fowl er et al  2009) . 
Invitro and in situ erosi on m odels are the m ost comm only used method sto invest igate 
the short term  performance of newerosi onformulations(Shellis et al 2011). Currently, there 
is no validated clinical methodol ogy or clinical index to monitor the progressi on of erosive 
tooth wear and enamel tissue loss (Shellis et al 2011) , and most of the devices used for 
detection of changes in mineral content can only be performed on specially prepared 
specimens (Attin 2006) .  In situ erosion models involve the use of  appliances or other devices 
in the human mouth that simulate the process (Zero 1995) and they allow the effect of an 
erosive challenge to be evaluated under intra oral conditions but with somecontrolled 
experimental variables. In situ models are placed in between the continuum of in vitro models 
and clinical studi es and can provid e evidence of the potenti al effect of new therapies in 
inhibit ing demineralization and prom oting remineralizat ion (Zero 1995)
.However, the 
extrapol ation of their result to clinically relevant evidence must be carefully considered.
Anerosi on in situmodel will be used in this study  to invest igate the efficacy of an 
experimental dentifrice in promoting enamel remineralizat ion of previously  softened enamel. 
Page 12 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 12 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20171.1 Mechanism of Action/Indication
The test dentifrice formulationbeing invest igated contain s 0.254% w/w NaF, 
equivalent to 1150 ppm fluori deand 5% KNO 3. The efficacy of the experimental  dent ifrice in 
enhancing enamel  remineralizat ion is being investigated in an in situ intraoral model with 
bovine enamel specimens in healt hy subjects.
1.2 Background and Rationale
Justification and need to perform the study 
The experimental  formulation tested in this study is based on the current ly marketed
Sensodyne Pronam el dentifrice and tested in vitro for a superi or performance.In order to 
support the experimen tal dentifrice market introducti on in the US, an in situ invest igation 
comparing the experimental dentifrice with a  f luoride free placebo dentifrice (primary 
objective) and with a  r elevant marketed dentifrice is needed (secondary  object ive) to 
investigate the efficacy inenhancing remineralizat ion and prevent ing demineralization. 
Therefore, t he aim o f this study  is to investigate the perform ance of an experimental  dent ifrice 
formulation in prom oting enamel remineralizatio n and inhibit ing post-treatm ent enamel 
demineralizat ion in an in situerosi on model, in comparison with a fluori de-free placebo and 
with a marketed com petitor dentifrice product .
The in situmodel to be used in this study  has been extensively used to investigate the 
perform ance of the currently marketed Sensodyne Pronam elin previ ously published studi es 
(Barl ow et al 2009) and other GSK CH studi es (
, GSK -Z3480664 , , GSK -Z6961385) . 
Study and dose rationale
This clinical invest igation will use a previ ously published in situ remineralizat ion 
model (Barl ow et al 2009) which consists of placin g pre-eroded sterilized bovine enamel 
specimens intra orally using a palatal  appliance and testing the enhancement of 
remineralizat ion and prevent ion of demineralization performance of the experimental 
formulation after 2 and 4 hours post treatm ent applica tion based on surface micro hardness 
measurements . Details of enamel and palatal  appliance preparat ions are specified in protocol 
Secti on 7.3 .  The pal atal appliances (Figure 1) will be made for each eligible subject, and each 
will carry two plast ic holders containing a total of eight bovine enamel specimens (four in 
each ho lder). 
Page 13 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 13 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017This will be a rando mized, controlled, single center, single -blind (to the dental 
examiner and specimen analysts), 3 peri od, 3 treatment, cross -over, in situ study design. Each 
subject will brush their teeth once wi th each of the study  products as described below. Ateach 
visit, and under supervisio n while the intraoral  appliance is in place, the subjects will brush
the buccal surfaces of their natural teeth using 1.5 g dentifrice and a soft toothbrush for 25 
seconds to create a slurry. Subjects will be instructed not to expectorate the slurry . Subjects
will then swish the slurry  around the mouth for 95 seconds to permit direct contact of the 
dentifrice slurry  with the enamel specimens. The toothbrush however, will not come into 
contact wi th the en amel  specimens or the appliance as thi s coul d cause abrasi on on the enamel 
specimens. This will be fo llowed by  an intraoral remineralizat ion peri od of up to 4 hrs.
Figure 1:Schematic diagram of a) intraoral appliance, b) enamel specimens’ holder, c) enamel 
specimens placed in the holder and d) palatal appliance with enamel specimens in the mouth. 
Oral tolerance
GSK CH has run numerous similar in situ clinical invest igations with currently 
marketed and experimental Sensodyne Pronamel  formulations. In all those studi es, the 
products were generally well tolerated (  
, GSK -Z3480664 , GSK -Z6961385) .  Oral soft tissue assessments will be 
carried out at all visits, pre and post intra oral phase and all adverse events will be recorded.
Com plete informat ion for this compound may be found in the single reference safet y 
docum ent (SRSD), whi ch for this study  is the Safety Statem ent (SS ).
Page 14 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 14 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20172 STUDY OBJECTIVES AND ENDPOIN TS
Table 2-1 Study Objectives and Endpoints
Objective(s) Endpoint(s)
Primary
To investigate the efficacy of an experimental 
dentifrice containing 1150 ppm fluoride and5% 
KNO 3to enhance remineralization of enamel 
relative to a fluoride free placebo dentifrice.%SMHR after 4 hrs intraoral phase following a 
single exposure. 
Secondary
Efficacy
To inv estigate the efficacy of an experimental 
dentifrice containing 1150 ppm fluoride and5% 
KNO 3to inhibit demineralization of enamel relative 
to a fluoride free placebo dentifrice.%RER after 4 hrs intraoral phase following a 
single exposure.
To inv estigate the efficacy of an experimental 
dentifrice containing 1150 ppm fluoride and5% 
KNO 3to promote fluoride uptake in enamel 
relative to afluoride free placebo dentifrice.EFU after 4 hrs intraoral phase following a single 
exposure.
To inv estigate the efficacy of an experimental 
dentifrice containing 1150 ppm fluoride and 5% 
KNO 3to enhance remineralization, to inhibit
demineralization and to promote fluoride uptake 
in enamel relativ e to abenchmark comparator 
containing 11 00 ppm fluoride (Crest Pro Health ).%SMHR, %RER and EFU after 4 hrs intraoral 
phase following a single ex posure.
Safety
To evaluate the oral tolerance of an experimental 
dentifri ce containing 1150 ppm fluoride and 5% 
KNO 3following a single brushing event. Proportion of treatment emergent
oral adverse ev ents post 4 hours intraoral 
exposure. 
Exploratory
To make all paired comparisons of the efficacy of 
an experimental dentifrice containing 1150 ppm 
fluoride and5% KNO 3after 2 hours of intraoral 
exposure to enhance remineralization of enamel , 
to inhibit demineralization of enamel and to 
promote fluoride uptake in enamel.%SMHR, %RER and EFU after 2 hrs intraoral 
phase following a single exposure.
To characterize the efficacy of theexperimental 
dentifrice containing 1150 ppm fluorid eand5% 
KNO 3; the fluoride free placeb o;and the 
benchmark comparator containing 11 00 ppm 
(Crest Pro Health )after 2 and 4 hours of intraoral 
exposure on resistance to acid challenge . Summary statistic table of ARR after 2 and 4 hrs 
intraoral phase. 
Abbreviations: SMHR: Surface micro hardness recovery, RER: Relative erosion resistance, EFU: Enamel 
fluoride uptake, ARR: Acid resistance ratio
Page 15 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 15 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017This study  will be considered successful if the experimental dentifrice demonstrates a 
statist ically significant enhancement of remineralizat ion, as measured by %SMHR in 
comparison wi th the pl acebo dentifriceafter 4 hours intraoral phase. 
3 STUDY DESIGN AND SUBJECT POPULATION
This will be a randomized, controlled, single center, single -blind (to the d ental examiner and 
specimen analysts), 3 period, 3 treatm ent, cross -over, in situdesign which consists of placing 
pre-eroded bovine enamel specimens intra orally using a palatal  appliance and testing the 
remineralizing performance of the experimental, comparator and placebo dentifrices 2 and 4 
hours post treatm ent applicat ion, based on surface micro hardness measurements. This study 
will be carried out in healt hy adults with a maxillary  dental  arch suitable for the retenti on of 
the pal atal appliance. A sufficient number of healt hy subjects will be screened so that up to 66 
subjects are rando mized to participate in the study to ensure 60 evaluable subjects complete 
the enti re study . Subjects will be recrui ted from an existing panel of  subjects pre-fitted wi th a 
palatal appliance (IRB approved panel ).For a subject whose appliance does not 
fit adequately and for whom adjust ment of the appliance is not sufficient to obtain proper fit, 
the subject may have a new appliance made.Surface microhardness (SMH) measures 
changes in the mineral content of enamel, and isused to calculate surface micro hardness 
recovery (%SMHR ), relative erosi on resistance (%RER )and acid resistance ratio(ARR ). 
Fluori de uptake of the experimental  dentifrice will be assessed by enamel fluori de uptake 
(EFU) measurements. For each treatm ent and subject thesemeasurements will beperformed 
on the same enamel specimen, in the four replicates for each time point. The erosive acid 
challenge , with a commercially available grapefrui t juice,will be carried out ex vivo and 
therefore doesnot pose a risk to the subject’s teeth .The overall study  design sequence of 
events is sketched in Figure 2. 
For the aim of this study , a fluori de-free placebo dentifrice will be used as comparator to 
establish if the fluori de present in the experimental dentifricecan provide and enhancement of 
remineralizat ion and prevent ion of demineralizatio n in this in situ model. Addit ionally , a
relevant commercially available dentifricecontaining 1100 ppm fluoride (as stannous 
fluori de, SnF 2) will be used as a com parator (secondary object ives) to invest igate the superi or 
perform ance of the experimental  dentifrice in enhanc ingremineralizat ion and prevent ing
demineralizat ion. 
Page 16 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 16 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Figure 2:Schematic diagram of the experimental phase for each subject and treatment showing the 
flow of events at each visit. 
In this study  there will  be 4 visi ts, 
1 screening visit to assess subject eligibilit y and 3 treatment 
visits to assess product efficacy , where the treatment product will be dispensed and used 
under the supervisio n of a suitably trained study  site personnel. Prior to each treatm ent visit, 
there will be a washout period of a minimum of3 days. During this periodsubjects will use 
their own dentifrice for at least one day , and afluori defreedentifrice(provi ded) for
two days 
prior to the next scheduled visit (including in the morning of the scheduled visit) to minimize 
any carry-over effects of the fluori de toothpaste . Based on previ ous studi es, two days are 
sufficient to minimize any carry -over effect. 
According to ICH gui delines, for a study  to b e classed as truly double blind, not only 
does the examiner (and any appropriate member of staff who may be involved in the 
dispensing of products, analysis of data etc.) need to be blinded to the treatment the subject 
receives, but the test products must be ident ical in every way (colour, flavour, appearance, 
packaging). Given that it is almost impossible to ensure identical appearance, taste and 
packaging for the dentifrices evaluated in this study , the level of blindness for this study  is 
described as ‘examiner blind’ only.
The study statistician and other empl oyees of the Sponsor who may influence study 
outcom es are blinded to the product allocat ion of subjects. The examiner and specimen 
analyst will be blind ed to the treatm ent received. To ensure the examiner and specimen
analysts remain blinded throughout the study, the examiner and specimen analysts arenot Baseline SMH      
(B)Erosive challenge 1 Post erosion SMH
(E1)Enamel specimens 
placed on 
appliance intraoral appliance placed 
in subject ’s mouth 
5 min equilibration 
25 sec toothbrushing
95 sec swirling 
2 hrs and 4 hrs intraoral 
phasePost erosion 
SMH (E2)Erosive challenge 2 After remin SMH 
(R)
Measurement Acid exposure In situEnamel specimens 
removed from 
appliance at 2hrs 
and 4 hrs
Legenspecimens processed 
through sterilizer
EFU
Page 17 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 17 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017permitted in the room  while product is dispensed. All study  products will be overwrapped to 
conceal any labelling. In addition, subjects will receive treatm ent in a separate area from 
where clinical assessments are perform ed.The dispensing staff will not be involved in any 
clinical assessments or laboratory  analysis during the study . Study  site staff that perform study 
consent can only also dispense thestudy product but can not perform  any other study activi ty. 
Laboratory  personnel that carry  out the specimen analysis will also be blinded to product 
allocat ionand not be invo lved in any clinical assessment.
4 SUBJECT SELECTION
This study  can fulfill its object ives only if appropri ate subjects are enrolled.  The following 
eligibilit y criteria are designed to select subjects for whom participat ion in the study  is 
considered appropri ate.  All relevant medical and nonmedical condi tions shoul d be taken into 
consideration when deciding whether a particular subject is suitable for this protocol.  
4.1 Inclusion Criteria
Subject eligibilit y shoul dbe reviewed and documented by an appropri ate member of the 
investigator’s study  team  before subjects are included in the study .
Subject must meet all of the following inclusio n criteria to be eligible for enrollment into the 
study :
1.Evidence of a personally signed and dated informed consent 
2.Male and female subject swho, at the time of screening , are between the ages of 18 and 65 
years, inclusive.
3.Subject who iswilling and able to comply  with schedul ed visi ts, treatm ent plan ,and other 
study  procedures.
4.Good general and mental healt h with, in the opinio n of the invest igator or medically  
qualified designee. N o clinically  significant and relevant abnormalit ies in medical history  
or oral  examination. 
5.Male subject able to fat her children and female subject of childbearing potential and at 
risk for pregnancy must agree to use a highly effective method of contraception 
throughout the study  and for 5 days after the l ast dose of assigned treatment.  
6.Good oral healt h without lesions of  the oral  cavit y that coul d interfere wit h the study  
evaluat ions. 
7.Maxillary dental arch suitable for the retention of the palatal appliance
8.Unstimulated salivary flow rate of at least 0.2 mL/minute and a stimulated salivary flow 
rate of at least 0.8 mL/minute
9.Understands and is will ing, able and likely to comply wit h all study  procedures and 
restri ctions.
Page 18 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 18 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20174.2 Exclusion Criteria   
Subjects with any o f the following characteri stics/condit ions will not be included in the study :
1.Subjects who are investigational site staff members direct ly involved in the conduct of the 
study  and thei r family members, si te staff members otherwise supervised by the 
investigator, or subjects who are GSK emplo yees di rectly involved in the conduct of the 
study .
2.Parti cipation in other studi es invo lving investigat ional drug(s) within 30 days prior to 
screening visit.
3.Parti cipation in other studi es invo lving investigational oral care or cosm eticproducts
within 30 days pri or to screening visit.
4.Acute or chronic medical or psy chiatric condit ion that may increase the risk associ ated 
with study  parti cipat ion or invest igational product administration or may  interfere wi th the 
interpretati on of  study  resul ts and, in the j udgment of the invest igator, would make the 
subject inappropriate for entry  into this study .
5.Pregnant female subject (self –reported ).
6.Breastfeeding female subject .
7.Known or suspected intolerance or hy persensi tivity to the study  materials (or cl osely 
related com pounds) or any  of their stated ingredients. 
8.Unwillin g or unable to com ply wit h the l ifestyle guidelines described in this protocol. 
9.Medicat ion that m ay interfere si gnificant ly wit h the saliva flow in the judgment of the 
investigator . Should new medicat ions that may interfere with the saliva flow be added , a 
second salivary  flow test will be perform ed.
10.Subject withany condi tion that woul d impact on the irsafety or wellbeing or affect their
abilit y to understand and follow stud y procedures and requirements.
11.Any sign of  grossly cari ous lesions (active), moderate or severe peri odontal  condi tions, or 
severe tooth wear .Subject presenting at screening with minor caries may continue in the 
study  if thei r cari ous lesi ons are repai red pri or to the first treatment visit of the study .
12.Wears oral appliance or orthodontia ( besides subjects wearing permanent l ower retainers , 
which are eligible) .
13.Recent history  (within the l ast year) of alcohol  or other substance abuse.
14.Subject who haspreviously been enrolled in this study . 
4.3 Randomization Criteria
Subjects will be randomized into the study  provided they have satisfied all subject selection 
criteria.
4.4 Lifestyle Guidelines
During the entire study :
Page 19 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 19 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Subjects will be asked to stop using their own dentifrice two day s before Visit2, 3 and 
4, when they will use the provided fluori de -free dentifriceand toothbrush to brush 
their teeth (including in the morning ofthe scheduled Vi sit).
Subjects will not be permitted to use any fluori de-containing products (including 
mouthwashes) for 2 day s prior to Vi sit 2, 3 and 4. 
Subjects will be requested not to have any elective dental  procedures including teeth 
professio nally cleaned other than those performed within the study  (excluding 
emergency dental  treatm ent). 
During Visit 2, 3 and 4:
Subjects shoul d refrain from talking for the first hour af ter brushing on each treatm ent 
visit.
Subjects shoul d not leave the study  site during the 4 hours treatm ent phase while 
wearing the intraoral appliances . 
4.4.1 Meals and Dietary Restrictions
Subjects m ust abstain fro m all food and drink ( except water) at least 30 minutes prior 
to their scheduled Visit2, 3 and 4. 
During Visit 2, 3 and 4:
Subjects will not be permitted to drink water for the first two hours of the intraoral  test 
period(after treatm ent administration) , but may drink water after the first two hours 
under the supervisio n of the study  personnel. 
Subjects will not be permi tted to eat during the four hours’ durati on of the intraoral 
test peri od (after treatm ent administration) . 
4.5 Screen Failures
Screen failures are defined as subjects who consent to pa rticipate in the clinical study  but are 
not subsequent ly randomized . In order to ensure transparent reporting of screen failure 
subjects, a minima l set of screen failure inform ation will include demography, screen failure 
details (e.g., withdrawal o f consent), eligibilit y criteria, and any  serious adverse events. 
Individuals who do not m eet the cri teria for parti cipati on in this study  (screen failure) may not
be re -screened.
Page 20 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 20 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017For a subject whose appliance does not fit adequately and for whom adjustm ent of the 
appliance is not sufficient to obtain proper fit, the subject may have a new appliance made. 
This will not be considered a screen failure. The subject may repeat the appliance try-in 
porti on of  the screening visit after fabricat ion of the new appliance. 
4.6 Sponsor’s Qualified Medical Personnel
The contact informat ion for the sponsor's appropriately qualified medical/dental personnel for 
the study  is docum ented in the study  contact list in the Trial Master File .
The contact number can be used by invest igatio nal staff if they are seeking advice on 
medical/dental quest ions or problems; however, it should be used only in the event that the 
established communication pathways between the invest igational site and the study  team are 
not available. It is therefore intended to augment, but not replace, the established 
communicat ion pathways between the invest igational site and the study  team for advice on 
medical/dental quest ions or probl ems that may arise during the study .The contact number is 
not intended for use by the subject direct ly, and if a subject calls that number, he or she will 
be directed back to the investigat ional site.
To facilitate access to appropriately qualified medical/dental personnel  on study -related 
medical/dental quest ions or problems, subjects are provi ded with a
 contact card. The contact 
card contains, at a minimum, protocol  identifiers, subject study  numbers, contact informat ion 
for the invest igational site, and contact details inthe event that the invest igational site staff 
cannot be reached to provide advice on a medical question or problem ident ified from the 
subject’s healthcare professio nal other than the investigator.
5 STUDY TREATMENTS
5.1 Blinding and Allocation to Treatment/ Randomization
Blinding
This is a single blind study , with the examiner being blind to the treatment each subject 
received. Subjects will not be blind to the tr eatm ent that they  are receiving. 
The study  stati stician and other em ployees of  the Sponsor who may influence study  outc omes 
are blinded to the product allocat ion of subjects. The examiner will be blinded to the treatment 
received. To ensure the examiner and specimen analysts remain blinded throughout the study , 
the examiner andspecimen analysts arenot permit ted in the room  whilst product i s dispensed . 
In addition, subjects shoul d be treated in a separate area. The dispensing and laboratory  staff 
will not be invo lved in any efficacy assessments during the study .Study  site staff that perform 
study  consent can only also dispense thestudy product but can not perform any other study 
Page 21 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 21 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017activit y.Laboratory  personnel that carry out the specimen analysis will also be blinded to 
product allocation and not be invo lved in any clinical assessment.
Allocation to treatment sequence
Subjects will be assigned to study  product sequence in accordance with the randomizat ion 
schedule generated by a Vendor under the supervisio n of the Biostati stics Depart ment, GSK 
CH, prior to the start of the study , using a validated program .Subjects will be randomized in a 
Williams square design balanced for first period carry over.
Randomization
GSK CH will provide a randomizat ion schedule to the invest igator and, in accordance with 
the randomizat ion numbers, subjects are pl anned to receive all treatm ents in a pre -determined 
order as specifie d by the rando misat ion schedule .  
A unique screening number will ident ify each subject screened for study  participat ion. 
Screening numbers will be assigned in ascending numerical order as each subject signs their 
consent form. Subjects who meet all inclusio n and exclusi on criteria will be randomized 
according to the rando misat ionschedule. Randomisat ion numbers will be assigned in 
ascending numerical order as each subject is determined to be fully eligible.
The study  site will receive two versions of the randomisat ion schedule, each in a sealed 
envelope and clearly marked as ei ther “For Dispensing” or “Emergency Use Only”. The “For 
Dispensing” schedule will contain the lis t of randomisat ion numbers only and will not include 
any coded description, just a letter A
, Bor C. The ‘Emergency Use Only’ rando misat ion 
schedul e will only be removed from the sealed envelope in an emergency situation. This 
schedule will have a randomi sation number followed by a sequence of letters A, B or C. The 
schedule will have a f ootnote wi th a key f or A, Bor C identifying the threetreatm ent regimen 
sequences .
However, to m aintain the blinding of the study  asfar as possible, all treatment allocat ions for 
all randomisat ion numbers on thisrando misation schedule will be masked with scratch -off 
panels. Only  the panels requi red f or the unblinding the particular subject should be removed.
5.2 Breaking the Blind
At the initiation of the study , the study site will be instructed on the method for breaking the 
blind.  The method will bemanual .  Blinding codes shoul d be broken only in emergency 
situations for reasons of subject safet y.  W henever possible, the invest igator or sub-
investigator should consult with a member of the study  team  prior to breaking the blind unless 
the delay woul d endanger the subject’s healt h.  When the blinding code is broken, the reason 
must be fully docum ented and entered in the case report form (CRF). When documenting in 
Page 22 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 22 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017the CRF,the site shoul d ensure that no text description has the potenti al to un blind any other 
subjects.
Any AE or serious AE (SAE) associ ated with breaking the blind must be recorded and 
reported as specified in this protocol . The study  site is requi red to infor m the IRB/EC if the 
blind is broken. 
5.3 Subject Compliance
Subjects will complete diary cards during the 2 days of washout period prior to the treatm ent 
visit. 
Study  treatm ent will be administered under the supervisio n of invest igator site personnel.  
5.4 Investigational Product Supplies
Test Product Comparator 
ProductPlacebo Product
Product Name Experimental den tifrice 
containing 0.254% w/w 
sodium fluoride ( 1150 
ppm fluoride) and5% 
KNO 3; plus 0.25% 
PVM/MA copolymer 
and 2.5% sodium 
lactateCrest Pro Health
Sensit ivity & 
Enamel Shield
containing 0.454% 
w/w stannous 
fluori de(1100 ppm  
fluori de)Fluoride free placebo 
containing 5 % KNO 3
(0 ppm fluoride); plus
0.25% PVM/MA 
copolymer and 2.5% 
lactate   
Product 
Formulation 
Code (MFC)Commercially
available (US 
marketed)
Dose 1.5 g 1.5 g 1.5 g
Route of 
AdministrationOral Oral Oral
Dosing 
InstructionsSubjects will apply a full ribbo nof the allocated product and b rush the 
buccal surfaces of their natural teeth for 25 timed seconds and then 
swish the resul ting toothpaste slurry  around the m outh, wi thout further 
brushing, for a timed period of 95 seconds. After expectorating the 
slurry, the subjects will gent ly rinse their mouths with 15 mL of tap 
water for 10 seconds b efore expectorating again
Sundry items : 
Page 23 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 23 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Oral-B Sensi  Soft Manual Toothbrush 
oManual toothbrush to apply test and washout dentifrice 
Fluori de freetoothpaste 
oFluori de free dent ifrice to brush theirteeth during the 2 days pri or to treatment 
visit
Countdown timer
oTo ensure accurate brushing time 
Diary cards (to be supplied by  GSK Warren)
oRecord washout product use.
Dosing cups
oFor ri nsing after brushing.
Unflavoured gum base
oFor stimulated saliva samples collection
All other items such as saliva sampling collection equipment will be supplied by the study 
site.Grape fruit juice (commercially available) for the ex vivo acid challenge will also be 
sourced by  the study  site. 
5.4.1 Dosage Form and Packaging
The contents of the label will be in accordance with all applicable regulatory  requi rements and 
will be the responsibilit y of the Clinical Supplies Department, GSK CH .
The fluori de-free washout toothpaste will be supplied in plain white tubes with a study label 
affixed. Each subject will receive a sufficient number of tubes to cover usage during the 
washout phase (for 2 day s prior to Vi sit 2, 3 and 4). 
The experimental  and placebo dentifriceswill be supplied in plain white tubes. The 
comparator dentifri ce will be sourced from the US market. All study products (experimental, 
comparator and pl acebo dent ifrices) will be over-wrapped in white vinyl to maintain the study 
blind as much as possible.
Each tube will have a study  label affixed. Each study  label will contain, but not be limit ed to, 
protocol  number, product code letter(for treatm ent products only), directions for storage, 
emergency contact tel ephone number and “For Clinical Trial Use Only”.
Toothbrushes and countdown timers will be supplied in the ir commercial packaging.
Page 24 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 24 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Care shoul d be taken with the supplied study  products and their labels so that they are 
maintained in good condi tion. It is important that all labels remain intact and legible for the 
durati on of the trial. Subjects shoul d be instructed to not remove or deface any part of the 
study  label.
5.4.2 Preparation and Dispensing 
Test, control and placebo dentifrices and manual toothbrush will be dispensed by qualified 
unblinded site personnel according to the dosing instruction s(Sect ion 5.4).
5.5 Administration
During Visit 2, 3 an d 4 an d following the pre treatm ent assessments, a suitably trained study 
site designee will place the palatal  appliance holding eight bovine tooth enamel specimens in
thesubjects’ mouth followed by an equilibrat ion period of at least 5 minutes. Following the 
equilibration phase, and under thesupervisio n of a trained unblinded study  site designee , the 
subject will brush theirown teeth fo llowing the dosing instructions (Section 5.4). 
5.5.1 Medication Errors
Medicat ion errors m ay resul t, in thi s study , from the administrati on or consumption o f: 
the wrong product,
by the wrong subject, 
at the wrong time, 
or at the wrong dosage strength 
Such medicat ion errors occurring to a study participant are to be captured in the CRF. In the 
event of m edicat ion dosing error, the sponsor should be notified immediately .
Medicat ion errors are reportable irrespect ive of the presence of an associated AE/SAE, 
including:
Medicat ion errors invo lving subject exposure to the invest igational prod uct;
Potenti al medicat ion errors or uses outsi de of what is foreseen in the protocol  that 
do or do not invo lve the participat ing subject.
Whether or not a medication error is accompanied by an AE, as determined by the 
investigator, the medication error and, if applicable, any associ ated adverse event(s) is 
captured on an adverse event (AE) CRF page.
Page 25 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 25 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20175.6 Investigational Product Storage
The invest igator, or an approved representati ve, will ensure that all invest igational products 
including any comparator, market ed products and washout products are stored in a secured 
area with controlled access under requi red storage condi tions and in accordance with 
applicable regulatory  requi rements and product l abel.
Site system s must be capable of measuring and docume nting (for example, via a log) 
minimum and maximum temperatures for all site storage locations.  This shoul d be captured 
from the time of investi gational product receipt throughout the study .  Even for continuous 
monitoring systems, a log or site procedure that ensures active evaluat ion for excursi ons 
shoul d be available. The operati on of the tem perature -monitoring device and storage uni t (for 
example, refrigerator), as applicable, shoul d be regul arly inspected to ensure it is maintained 
in working order. 
Any excursionsfrom the product -label storage condit ions shoul d be reported upon discovery.  
The site shoul d actively  pursue options for returning the product to the storage condi tions as 
described in the labeling, as soon as possible.  Deviat ions from the storag e requirements, 
including any  actions taken, must be documented and reported to the Sponsor.  
Once an excursi on is ident ified, the invest igational product must be quarant ined and not used 
until the Sponsor provi des docum entati on of  permissi on to use the i nvest igational product.  It 
will not be considered a protocol deviat ion if the sponsor approves the use of the 
investigat ional product after the temperature excursion. Use of the investigational product 
prior to sponsor approval will be considered a proto col deviat ion.  Specific details regarding 
inform ation the site should report for each excursion will be provided to the site. 
5.7 Investigational Product Accountability
All products supplied are for use only in this clinical study  and shoul d not be used forany 
other purpose.
Study  treatments must be received by a desi gnated person at the study  site, handled and stored 
safely and properly , and kept in a secured location to whi ch only the staff have access. Upon 
recei pt, all study  treatm ents shoul d be stored according to the instructi ons specified on the 
treatm ent labels. Clinical supplies are to be dispensed only in accordance with the protocol.
The invest igative site must maintain adequate records document ing the recei pt, use, loss, or 
other disposi tion of the invest igational product supplies.  All study  drugs will be accounted 
for using a drug accountabilit y form/record. 
The inventory  must be available for inspect ion by the study  monitor during the study . 
Moni toring of treatm ents accountabilit y will be performed by the field monitor during site 
visits and at the complet ion of the study .
Page 26 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 26 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20175.7.1 Destruction of Investigational Product Supplies 
All invest igational study  treatments shipped for this clinical trial will be returned to the 
Sponsor at the termination of the study .  At the conclusi on of the study , the Principal 
Invest igator or an appropriate designee, and a representative of GSK CH will inventory  all 
used and unused investigational study  treatm ent.  The study  treatm ent inventory record for 
returned study treatm ent will then be completed. All invest igational product for this clinical 
study  (empty  containers), as well as all unused study  product will be returned to the GSK CH 
Clinical Supplies Department designated vendor using the return instructions provided. 
5.8 Concomitant Treatment(s)
All conco mitant treatm ents taken during the study  must be recorded with indicat ion, unit 
dose, daily dose, and start and stop dates of admin istrati on.  All subjects will be quest ioned 
about concomitant treatment at each clinic visit.
Treatments taken within 30days before Screening visit will be docum ented as a prior 
treatm ent.  Treatm ents taken after the screening visitwill be docum ented as conco mitant 
treatm ents.
6 STUDY PROCEDURES
6.1 Visit 1 –Screening
Informed Consent
The investigator, or a person designated by the invest igator, will obtain written informed 
consent from each subject before any study -specific activit y is performed.  The invest igator 
will retain the original o f each subject's signed informed consent document.
The invest igator, or designee, must explain to th e subjects the aims, methods, objectives, and 
potenti al hazards o f the study , and that they  arecompletely free to ref use to enter the study  or 
to wi thdraw from  it at any  time.
Appropriate forms for docum enting a written consent will be provided by the invest igator or 
by GSK CH. The invest igator, or designee, should sign and date the consent form to con firm 
that the consent process was com pleted correctly . The subject will be provided wi th a copy  of 
their signed and dated consent form and any other written informat ion which they shoul d be 
instructed to retain.
If, during a subject’s participation in the study , any new inform ation becomes available that 
may affect the subject’s willingness to participate in the study , each ongoing subject shoul d 
receive a copy  of this new inform ation and be re -consented into the study . Subjects shoul d be 
provi ded wi th a copy  of the signed and dated amended consent form . The date of  consent will 
be recorded on the CRF.
Page 27 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 27 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Demographics and ethnicity
The following demographic parameters will be captured by the Invest igator or designee and 
recorded on the CRF: year of birth, age, gender, race, and ethnicit y. Ethnicit y will be self-
reported and the choices offered will be Hispanic or Latino and Not Hispanic or Latino. 
Ethnicit y will  be captured by  the Investi gator or desi gnee and recorded on the CRF.
Medical History and Prior medications 
Medical history  will be assessed as related to the inclusio n/exclusio n criteria by the 
Invest igator or medically  qualified designee. Details of any relevant medical or surgi cal 
history  (within the last year), including allergies or drug sensit ivity, will be recorded on the 
CRF. Any priortreatm ent taken in the 30 days prior to the S creening Visit  will be recorded as 
per Section 5.8 in CRF . 
Screening Oral Hard Tissue assessment 
OHT examinat ion will be carried out at the Screening visit as described in Section 7.2 by 
dental  examiner or clinically qualified designee .Assessment will be recorded in the CRF. 
Screening Oral Soft Tissue assessment 
OST examinat ion will be carried out at the Screening visit as described in Section 7.2by 
dental  examiner or clinically qualified designee . Assessment will be recorded in the CRF. 
Unstimulated salivary flow rate
Unsitumulated salivary  flow rate will be measured at the screening visit as described in 
Secti on 7. 4by dental examiner or clinically qualified designee .
Stimulated salivary flow rate
Stimulated salivary flow rate will be measured at the screening visit as described in Secti on 
7.
4by dental examiner or clinically qualified designee .
Inclusion and Exclusion criteria
The invest igator, or a person designated by the investigator, will review the Inclusio n and
Exclusio n criteria as per Secti on 4.
Subject eligibility
Subject eligibilit y will be reviewed as per Secti on 4.
Try-In of Palatal Appliance
Palatal appliances (Figure 2)will be fitted and checked for comfort attheScreening visit. 
Subjects will be asked to wear thei r appliances for up to 15 minutes to determine comfort, fit 
and wearabilit y. Appliances will be adjusted as needed. As indicated in section 7.3, intraoral 
Page 28 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 28 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017appliances will be fabricated as described in the work instructions docum ent. For a subject 
whose appliance does not fit adequately and for whom adjustm ent of the appliance is not 
adequate to ob tain proper fit, may have a new appliance made under IRB approv ed protocol 
.  The subject may repeat the appliance try-in porti on of the screening visit after 
fabricat ion.
Dispense wash out products and diary cards
Subjects will be dispensed wi th the wash out toothbrush and the fluoride freetoothpaste touse 
during the washout period. Subjects will be instructed to brush their teeth with the fluori de 
free toothpaste during the 2 days prior to Visit 2, 3 and 4 (including the morning of the 
treatm ent visi t). Subjects will receive a d airy card to record twi ce daily toothbrushing wit h the
washout assigned product during the 2 days washout period.
Adverse Events and Incidents 
Adverse Events and Incidents will be recorded in the CRF as described in Sect ion 8. 
To prepare for study participat ion, subjects will be instructed on the use of the Lifest yle 
Guidelines and Conco mitant Treatm ent(s) sections of the protocol.
Inform ation will be recorded in the CRF . 
6.2 Study Period
There will be an interval of at least3days between study periods (i.e., administration of 
subsequent doses of invest igational product will not occur until at least 3days after the 
previous dose of invest igational product).
6.2.1 Visit 2 – Period 1
Subjects will attend Vi sit 2 at least 3 days after Visit 1. Subj ectswill brush with their own
toothpaste for at least one day ,and with the provi ded fluori de free toothpaste for two day s 
prior to the visit. 
The fo llowing assessments will be conducted in the order written:
Concomitant Medication
Concomitant medications will be assessed as related to the inclusio n/exclusio n criteria by the 
Invest igator or m edically qualified designee. Any concomitant treatm ent taken throug hout the 
study  will be recorded in the CRF. 
Page 29 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 29 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Continued eligibility
Subject conti nued eligibilit y will be reviewed as described in Section 4.
Diary cards review
Invest igator or designee will review diary cards of wash out product usage during wash out 
period. 
Pre-Treatment Oral Soft Tissue assessment 
OST examinat ion as described in sect ion 7.2 by dental examiner or clinically qualified 
designee and recorded in the CRF. 
Randomiz e to treatment 
Subjects will be randomized to treatment order as descri bed in sect ion 5.1.
Place enamel specimens in palatal appliance 
Enamel specimens will be 
place in the palatal  appliance after they are processed through 
sterilizer as described in Sect ion 7.3.
Place palatal appliance in subject’s mouth . 
Asuitably  trained study  site designee will place the palatal  appliance in the subjects’ mouth 
followed by an equilibrat ion peri od of  at least 5 minutes. 
Supervised treatment
Study  products will be used fo llowing the instructions and under the supervisio n of study  site 
personnel as described in Section 5 .4. 
Palatal appliances intra oral phase –2 hours 
After completing the brushing procedures, subjects will wear their palatal appliance for 2 
hours ±10 min. After this period, th e study  site designee will remove the appliance and four
pre-designated enamel specimens will be removed and sent for analysis (Section 7.3for 
Laboratory  Procedures). External Data will be recorded and transferred to GSK CH as 
detailed in Sect ion 9.5.
Palatal appliances intra oral phase –4 hours 
After removing 4 specimens at 2 hours, the study  site designee will replace the palatal 
appliance in the subject’s m outh f or a further 2 hours ± 10 min (4 hours total ), after which the 
study  site designee willagain remove the palatal appliance. At this point, four pre-designated 
enamel specimens will be removed and sent for analysis (Section 7.3for Laboratory 
Procedures). External Data will  be recorded and transferred to GSK CH as detailed in Section 
Page 30 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 30 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20179.5. At the end of the intraoral  phase, and after all enamel specimens are removed, the 
appliance will be disinfected and stored at site until the next treatment visit.  
Post-Treatment Oral Soft Tissue assessment 
OST examinat ion as described in sect ion 7.2 
Adverse Events and Incidents 
Adverse Events and Incidents will be recorded in the CRF as described in Sect ion 8. 
Inform ation will be recorded in the CRF . 
6.2.2 Visit 3 – Period 2 
Subjects will attend Visit 3at least 3 days after Visit 2. Subjects will brush with their own 
toothpaste for at least one day , and wi th the provi ded fluori de free toothpaste for two day s 
prior to the visit. 
The fo llowing assessments will be conducted in the order written:
Concomitant Medication
Concomitant medications will be assessed as related to the inclusio n/exclusio n criteria by the 
Invest igator or m edically qualified designee. Any concomitant treatm ent taken throug hout the 
study  will be recorded in the CRF. 
Continued eligibility
Subject conti nued eligibilit y will be reviewed as described in Section 4.
Diary cards review
Invest igator or designee will review diary cards of wash out product usage during wash out 
period. 
Pre-Treatment Oral Soft Tissue assessment 
OST examinat ion as described in sect ion 7.2 by dental examiner or clinically qualified 
designee and recorded in the CRF.  
Place enamel specimens in palatal appliance 
Enamel specimens will be place in the palatal  appliance after they are processed through 
sterilizer as described in Sect ion 7.3
Place palat al appliance in subject’s mouth . 
Page 31 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 31 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017A suitably  trained study  site designee will place the palatal  appliance in the subjects’ mouth 
followed by an equilibrat ion peri od of  at least 5 minutes. 
Supervised treatment
Study  products will be used fo llowing the instructions and under the supervisio n of study  site 
personnel as described in Section 5.4. 
Palatal appliances intra oral phase –2 hours 
After completing the brushing procedures, subjects will wear their palatal appliance for 2 
hours ± 10 min. After this period, th e study  site designee will remove the appliance and four 
pre-designated enamel specimens will be removed and sent for analysis (Section 7.3for 
Laboratory  Procedures). External Data will be recorded and transferred to GSK CH as 
detailed in Sect ion 9.5.
Palatal appliances intra oral phase –4 hours 
After removing 4 specimens at 2 hours, the study  site designee will replace the palatal 
appliance in the subject’s m outh f or a further 2 hours ± 10 min (4 hours total ), after which the 
study  site designee will again remove the palatal appliance. At this point, four pre-designated 
enamel specimens will be removed and sent for analysis (Section 7.3for Laboratory 
Procedures). External Data will  be recorded and transferred to GSK CH as detailed in Section 
9.5. At the end of the intraoral  phase, and after all enamel specimens are removed, the 
appliance will be disinfected and stored at site until the next treatment visit.  
Post-Treatment Oral Soft Tissue assess ment 
OST examinat ion as described in sect ion 7.2 by dental examiner or clinically qualified 
designee and recorded in the CRF.  
Adverse Events and Incidents 
Adverse Events and Incidents will be recorded in the CRF as described in Sect ion 8. 
Inform ation will be recorded in the CRF . 
6.2.3 Visit 4 – Period 3
Subjects will attend Visit 4at least 3 days after Visit 3. Subjects will brush with their own 
toothpaste for at least one day , and wi th the provi ded fluori de free toothpaste for two day s 
prior to the visit. 
Page 32 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 32 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017The fo llowing assessments will be conducted in the order written:
Concomitant Medication
Concomitant medications will be assessed as related to the inclusio n/exclusio n criteria by the 
Invest igator or m edically qualified designee. Any concomitant treatm ent taken throug hout the 
study  will be recorded in the CRF. 
Continued eligibility
Subject conti nued eligibilit y will be reviewed as described in Section 4.
Diary cards review
Invest igator or designee will review diary cards of wash out product usage during wash out 
period. 
Pre-Treatment Oral Soft Tissue assessment 
OST examinat ion as described in sect ion 7.2 by dental examiner or clinically qualified 
designee and recorded in the CRF.  
Place enamel specimens in palatal appliance 
Enamel specimens will be place in the palatal  appliance after they are processed through 
sterilizer as described in Sect ion 7.3
Place palatal appliance in subject’s mouth . 
A suitably  trained study  site designee will place the palatal  appliance in the subjects’ mouth 
followed by an equilibrat ion peri od of  at least 5 minutes. 
Supervised treatment
Study  products will be used fo llowing the instructions and under the supervisio n of study  site 
personnel as described in Section 5.4. 
Palatal applia nces intra oral phase –2 hours
After completing the brushing procedures, subjects will wear their palatal appliance for 2 
hours ± 10 min. After this period, th e study  site designee will remove the appliance and four 
pre-designated enamel specimens will be removed and sent for analysis (Section 7.3for 
Laboratory  Procedures). External Data will be recorded and transferred to GSK CH as 
detailed in Sect ion 9.5.
Palatal appliances intra oral phase –4 hours
After removing 4 specimens at 2 hours, the study  site designee will replace the palatal 
appliance in the subject’s m outh f or a further 2 hours ± 10 min (4 hours total ), after which the 
Page 33 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 33 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017study  site designee will again remove the palatal appliance. At this point, four pre-designated 
enamel specimens will be removed and sent for analysis (Section 7.3for Laboratory 
Procedures). External Data will  be recorded and transferred to GSK CH as detailed in Section 
9.5. At the end of the intraoral  phase, and after all enamel specimens are removed, the 
appliance will be disinfected and stored at site until the next treatment visit.  
Post-Treatment Oral Soft Tissue assessment 
OST examinat ion as described in sect ion 7.2 by dental  examiner or clinically qualified 
designee and recorded in the CRF.  
Post-Treatment Oral Hard Tissue assessment 
OHT examinat ion will be carried out by dental examiner or clinically qualified designee . 
Assessment will be recorded in the CRF. 
Collect wash -out products
A suitably  trained study  site designee will collect the wash -out products from the subject. 
Adverse Events and Incidents 
Adverse Events and Incidents will be recorded in the CRF as described in Sect ion 8. 
Study conclusion
Subjects will be evaluated to determine if they completed all study procedures or if
they were discontinued from the study  early. If the subject discont inued at any po int
during the study , the primary  reason for wi thdrawal  should be recorded on the study
conclusion page of the CRF by  select ing one of the options below.
Subject did not meet study  criteria
Adverse event
Lost to follow up
Protocol  violation
Withdrawal o f consent
Other
Inform ation will be recorded in the CRF . 
6.3 Subject Withdrawal
Shoul d a subject attend Visit 2, 3or 4having used afluori de oral care product within the 
previous 2 days,or having consumed food or drinks within 30 minutes prior to the schedule d
Page 34 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 34 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017visit, or shoul d any other factor, in the opinio n of the invest igator, be thought to affect study 
outcom es (e.g. excessive alcoho l consumpt ion), every attempt will be made to reschedule the 
subject. If they  cannot be reappointed they will be wi thdrawn from  the study .
Subjects may withdraw from the study  at any time at their own request, or they may be 
withdrawn at any time at the discreti on of  the investigator or sponsor for safety  or, behavi oral 
reasons, or the inabilit y of the subject to com ply with the protocol -requi red schedule of study 
visits or procedures.  
The following circumstances requi re discont inuation of study treatm ent and/or premature 
subject wi thdrawal:
Protocol  violation that m ay impact the outcom e of the subject’s safet y
Withdrawal o f informed consent
Subject lost to follow -up 
Unblinding of the subject 
Pregn ancy
Death
If a subject is discont inued or prematurely withdraws from the study , reasons for 
discontinuat ion or withdrawal  and associ ated date must be documented in the relevant 
section(s) of the CRF. 
If a subject does not return for a scheduled visit, ev ery effort shoul d be m ade to contact the 
subject.  The Investigator or site staff should attempt to contact the subject twice.  After two 
attem pts, clinical  site staff must send a regi stered letter.  If no response is received fro m the 
subject, the subject will be considered lost to fo llow up.  All attempts to contact the subject 
and informat ion received during contact attempts must be documented in the CRF .  In any  
circumstance, every  effort shoul d be m ade to document subject outcome, if possible.  The 
investigator shoul d inquire about the reason for withdrawal, request that the subject return all 
unused investigational product(s), request that the subject return for a final visit, if applicable, 
and fo llow-up wi th the subject regarding any  unresolved adverse events (AEs).
It may be appropriate for the subject to return to the clinical  site for final safety assessments. 
Subjects shoul dbe quest ioned regarding their reason for withdrawal .  Assessments, at the 
investigator’s discret ion, will  include the following:
Oral soft ti ssue examinat ion
Oral hard ti ssue examinat ion
Lack of completion of all or any of the early terminat ion procedures will not be viewed as 
protocol  deviat ions so l ong as the subject’s safet y was preserved.
If the subject withdraws from the study  and also withdraws consent for disclo sure of future 
inform ation, no further evaluat ions shoul d be performed and no additional data shoul d be 
Page 35 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 35 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017collected.  The sponsor may retain and cont inue to use any data collected before such 
withdrawal  of consent.
7 ASSESSMENTS
Every  effort shoul d be made to ensure that protocol -requi red tests and procedures are 
completed as described.  However, it is antici pated that from time to time there may be 
circumstances, outsi de the control  of the invest igator that may make it unfeasible to perform 
the test.  In these cases, the investigator must take all steps necessary to ensure the safety  and 
well-being of the subject.  When a protocol -requi red assessment cannot be performed, the 
investigat or will docum ent the reason for the missed assessment and any corrective and 
preventative actions that he or she has taken to ensure that required processes are adhered to 
as soon as possible.  The study  team  must be informed of these incidents in a timely manner.
7.1 Efficacy 
In this study  there are no clinical efficacy  assessments perform ed. All efficacy assessments 
will be performed ex vivo on the enamel specimens rem oved at the times defined in the Study 
Procedures section of this protocol . Enamel specimen preparat ion and analysis are described 
inLaboratory  Procedures Secti on 7.3. 
7.2 Safety
The following safet y assessments will be performed at times defined in the Study  Procedures
section of this protocol.  
Oral Hard Tissue Examination ( OHT)
Where possible, this procedure shoul d be conducted by a single dental  examiner or clinically 
qualified designee for all subjects . Subjects with evidence of gross intra-oral neglect or the 
need for extensive dental  therapy  will be excluded.
The OHT examinat ion will assess grossly carious lesionsor erosive wear, enamel 
irregularit ies, tooth fracture, gross decay , decalcification and faulty restorati ons.
Observations will be listed as “Absent” or “Present” and condi tions noted as present will be 
described.  Examinat ion findings will be described and docum ented inthe CRF .  Any 
observat ion that changes from “Absent” to “Present” from the screening assessment must be 
recorded as an AE. 
Oral Soft Tissue Examination ( OST)
Page 36 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 36 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Where possible, this procedure shoul d be conducted by a single dental  examiner orclinically 
qualified designee for all subjects for the duration of the study . The examinat ion will be 
accomplished by direct observat ion and palpat ion with retracti on aids as appropri ate. The 
examiner will include examinat ion of the labial mucosa (including lips), buccal mucosa,
mucogingival folds, gingival mucosa, hard palate, soft palate, tonsilar area, pharyngeal area, 
tongue, sublingual are a, submandibular area and salivary  glands.
The results of the examinat ion will be recorded in the CRF as either norm al or abnorm al, wi th 
details of any abnormalit ies. Any post-treatm ent soft tissue abnorm ality, or worsening of a 
pre-exist ing condi tion, observed by the examiner orreported by the subject will be recorded 
on the CRF. Any abnorm alities, orworsening of pre-exist ing condi tions, that occur from 
Visit 2 onwards will  berecorded as AEs.   
7.3 Laboratory Procedures
All laboratory  procedures will be provided in a separate work instruction docum ent. The 
work instruction document will be prepared by PI or designee and reviewed by GSK CH 
(CRS or designee) in eDMS. The work instructio ndocument will be approved by PI or 
designee and CRS or designee, and stored in eDMS pri or to Screening Visit.
The work instruction document w ill cover, for example, the fo llowing elements : 
Preparation 
Preparati on of  enamel specimens
Preparati on of  test holders and palatal  a ppliances
Assembly o f the test holder
In vitro erosive challenge 
Efficacy measurements
Surface microhardness (SMH )
Enamel fluoride uptake (EFU)
Enamel Specimen Storage
All enamel specimen samples will be stored post completing the study  and retained for up to 
sixmonthsafter laboratory  procedures detai led in the work instruction isfinalized, as they 
may be subject to further analysis.
Page 37 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 37 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Specimen Retention
Laboratory  specimens will be retained by the study  site for up tosix months following 
database lock. Before destruction, clinical study site designee will contact the sponsor in 
writing request ing permissi on to destroy the specimens. Specimens will be destroy ed by 
autocl aving. The sponsor will provide approval in writing or provi de an alternate time period 
for destruction ofspecimens. Before destruction, GSK may have the option to require the 
transfer of a  n umber of specimens after reporting and unblinding the study  for further 
laboratory  analysis with the aim to develop new analyt ical techniques or perform other 
analyt ical tests. 
7.4 Salivary flow 
At the screening visi t, both stimulated and unst imulated saliva will be collected for evaluat ion 
of flow rates as part of the inclusio n criteria. Saliva samples collected will be destroy ed 
inmediatelly  after they aremeasured. 
Unstimulated salivary flow
For the unstimulated saliva collection, subjects will sit quietly for five minutes before 
beginning the treatm ent period. During the five-minute test period, they will be instructed to 
allow their saliva to pool, empt ying into a collection tube whenever they feel theyneed to 
swallow.  Samples will be weighed, pre/post collection and weights calculated (1g = 1ml).
Unstimulated saliva flow rate must be ≥ 0.2 ml/min. Saliva samples collected will be 
destroy ed immediately after they aremeasured. 
Stimulated salivary flow
For the stimulated saliva collection, subjects will chew on a piece of unflavoured gum base 
for one timed minute. After one minute, subjects will be instructed to swallow any pooled 
saliva. They will then chew the gum base for two timed minutes during which time they will 
empty any pooled saliva into a 
collection tube. Samples will be weighed, pre/post collection 
and weights calculated (1g = 1ml). Stimulated saliva flow rate must be ≥ 0.8 ml/min. Saliva 
samples co llected will be destroy ed immediately after they are measured. 
Page 38 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 38 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-20178 ADVERSE EVENT AND OTHER EVENTS OF SPECIAL 
INTEREST REPORTING
8.1 Definitions of Adverse Events and Serious Adverse Events
8.1.1 Adverse Event
An AE is any untoward medical occurrence in a clinical study  participant , temporally 
associ ated wi th the use of an investi gational or washout product or m edical  device, w hether or 
not consi dered rel ated to the invest igational or washout product or medical device .
NOTE: An AE can therefore be any unfavorable and unint ended sign (including an abnorm al 
laboratory  finding), symptom , or disease (new or exacerbated) tem porally associ ated with the 
use of a study  treatm ent.
Events Meeting the AE Definition :  
Any abnormal laboratory  test resul ts (hematol ogy, clinical chemistry , or uri nalysis) or 
other safet y assessments (eg, ECG, radio logical scans, vital sign measurements), 
including those that worsen fro m baseline, considered clinically significant in the 
medical and scient ific judgment of the investigator (ie, not r elated to progression of 
underlying disease).
Exacerbat ion of a chronic or intermittent pre -exist ing condit ion including either an 
increase in frequency and/or intensit y of the condi tion.
New condit ions detected or diagnosed after study  treatm ent administr ation even 
though it m ay have been present before the start of the study .
Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, symptoms, or the clinical sequelae of a suspected overdose of either study  
treatm ent or a conco mitant m edicat ion. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.
"Lack of efficacy" per se will not be reported as an AE or SAE. Such instances will be 
captured i n the efficacy assessments. However, the signs, symptoms, and/or clinical 
sequelae result ing from lack of efficacy will be reported as AE or SAE if they fulfil l 
the definit ion of an AE or SAE. 
Events NOT meeting the AE definition: 
Any clinically significant abnorm al laboratory findings (if applicable) or other 
abnorm al safety assessments which are associ ated with the underlying disease, unless 
judged by  the invest igator t o be m ore severe than expected for the subject’s condit ion. 
The disease/disorder being studi ed or expected progressi on, signs, or symptom s of the 
disease/disorder being studi ed, unless more severe than expected for the subject’s 
condi tion. 
Page 39 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 39 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Medical or surgical procedure (e.g., endoscopy , appendectomy ) is not the AE. The 
condi tion that l eads to the procedure is an AE (e.g., appendicit is).
Situations where an untoward medical occurrence did not occur (soci al and/or 
convenience admissio n to a hospital).
Anticipated day-to-day fluctuati ons of pre-exist ing disease(s) or condit ion(s) present 
or detected at the start of the study  that do not worsen. 
8.1.2 Serious Adverse Event
If an event is not an AE per defini tion above, then it cannot be an SAE even if serious 
condi tions are met (e.g., hospitalizati on for signs/symptoms of the di sease under study , death 
due to progression of disease).
A serious adverse event is any  untoward medical occurrence at any  dose that:
Results in death
Is life -threatening
The term  'life-threatening' in the definit ion of 'serious' refers to an event in which 
the participant was at risk of death at the time of the event. It does not refer to an 
event, which hypothetically might have caused death, if it were more severe ;
Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalizat ion signifies that the participant has been detained (usually 
involving at l east an overnight stay ) at the hospi tal or em ergency ward for 
observat ion and/or treatment that would not have been appropriate in the 
physician’s office or outpatient setting. Complicat ions that occur during 
hospi talizati on are AE. If a com plicati on prol ongs hospi talizati on or f ulfills any  
other serious criteria, the event is serious. When in doubt as to whether 
“hospitalizat ion” occurred or was necessary , the AE shoul d be considered serious.
Hospitalization for elect ive treatment of a pre -existing condit ion that di d not 
worsen from baseline is not considered an AE.
Results in persistent or signific ant disability/incapacity
The term disabili ty means a substant ial disrupt ion of a person’s abilit y to conduct 
norm al life f unctions.
This definit ion is not intended to include experiences of relat ively minor medical 
significance such as unco mplicated heada che, nausea, vomit ing, di arrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may interfere with or 
prevent every day life f unctions but do not constitute a substant ial disruption
Results in congenital anomaly/birth defect
Other situations
Medical  or sci entific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediately  life-threatening or resul t in death or hospitalizat ion but 
Page 40 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 40 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017may jeopardize the participant or m ay requi re medical or surgi cal intervent ion to 
prevent one of the other outcomes listed in the above definit ion. These events 
shoul d usually be considered serious.
Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias or convulsio ns that do not result in hospitalizat ion, or development of 
drug dependency  or drug abuse.
8.2 Reporting Period
8.2.1 Adverse Event
AEs will be collected from theend of the Screening Visit anduntil 5 days following last 
administration of the investi gational product . 
Medical occurrences that begin before the start of study treatm ent but after obtaining 
inform ed consent will be recorded on the Medical History /Curr ent Medi cal Condit ions sect ion 
of the case report form (CRF) not the AE sect ion.
8.2.2 Serious Adverse Event
SAEs assessed as related to study  parti cipat ion (e.g., invest igational product, protocol 
mandated procedures, invasive tests, or change in exist ing thera py) or rel ated to a GSK 
concomitant medicat ion will be recorded from the time a subject provides informed consent, 
which is obtained prior to the subject’s part icipation in the study , i.e., pri or to undergoing any 
study -related procedure and/or receiving i nvest igatio nal product and until 5 days days 
following last administration of the invest igational product.
SAEs assessed as not related to study  partici pation (e.g., invest igational product, protocol 
mandated procedures, invasive tests, or change in exist ing therapy ) or notrelated to a GSK 
concomitant medication will be recorded from the at least 1dose of investi gational product
and until 5 days fo llowing l ast administrati on of  the invest igational product. 
8.3 Reporting Procedures
The investigator and anydesignees areresponsible for detecti ng, documenting and reporting 
events that meet the definit ion of an AE or SAE and remain responsible for following up on 
AEs that are seri ous, considered related to the study  treatm ent or the study , or that caused the 
participant to di scont inue the study . 
The invest igator is to report all direct ly observed AEs and all AEs spontaneously reported by 
the study  subject. In addit ion, each study  subject will  be quest ioned about AEs. 
Each AE is to be assessed to determine if itmeets the criteria for SAEs.  If an SAE occurs, 
expedited reporting will fo llow local and internat ional regulat ions, as appropriate.
Page 41 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 41 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017When an AE/SAE occurs, it is the responsibilit y of the investigator to review all 
docum entati on (eg, hospi tal progress notes, laboratory , and diagnosti cs reports) related to the 
event.
The investi gator or si te staff will then record all relevant informati on regarding an AE/SAE in 
the CRF.
It is not acceptable for the invest igator to send photocopi es of the participant’s medical 
records to GSK in lieu of co mpletion o f the GSK /AE/SAE CRF page.
There may be instances when copies of medical records for certain cases are requested by 
GSK.  In this insta nce, all subject ident ifiers, with the except ion of the subject number, will be 
blinded on the copies of the medical records prior to submissio n to GSK.
The invest igator will attem pt to establish a diagnosis of the event based on signs, symptom s, 
and/or other clinical information.  In such cases, the diagnosis will be docum ented as the 
AE/SAE and not the individual signs/symptom s. Clinical AEs will be described by diagnosis 
and not by symptoms when possible (e.g., upper respi ratory  tract infect ion, seasonal allergy, 
etc. instead of runny nose).
Medical condi tions reported prior to the time period for reporting AEs/SAEs shoul d be 
recorded as part of the subject’s medical history .
AEs elicited by the investigator in a standard manner at the study  visits shoul dalso be 
recorded in the AE section of the CRF. Care will be taken not to introduce bias when 
detecting AE and/or SAE. Open -ended and non-leading verbal quest ioning of the participant 
is the preferred method to inquire about AE occurrence .
8.3.1 Adverse Event
All AEs will be reported on the AE page(s) of the CRF by the investigator or site staff.  It 
shoul d be noted that the form for collection of SAE informat ion is not the same as the AE
CRF.  Where the same data are collected, the forms must be completed in a consistent 
manner.  For example, the same AE term should be used on both forms.  AE shoul d be 
reported using concise medical termino logy on the CRF as well as on the form for collecti on 
of SAE inform ation.
8.3.2 Serious Adverse Event
A paper copy  of the SAE form provided in the invest igator study master file shoul d be 
completed as fully as possible. 
It is essent ial to enter the following informat ion: 
Protocol  and subject i dentifiers
Subject’s demography
Descript ion of events, with diagnosis if available
Page 42 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 42 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Invest igator opinio n of relationship to study  product 
Criterion for seri ousness.
The following are desirable and are of particular relevance for investigator and GSK CH 
assessment of the SAE report:
Date of onset of AE 
Date AE stopped, if relevant
Study  product start date
Study  product end date if relevant
Action taken on study  product
Outcom e if known
The SAE form, completed as fully as possible, must be e-mailed to the GSK CH Clinical 
Operati ons Safet y Reporting email box with the study  number and subject numb erin the 
subject line of the email immediately and under no circumstance should this exceed 24 
hours after study  site personnel learn of the event. The invest igator will submit any updated 
SAE data to the sponsor, immediately and under no circumstance should this exceed 24 
hours of it being available. The GSK CH Study Manager shoul d also be notified of the 
situation by  telephone or em ail.
Email Serious Adverse Events to:
The GSK CH Study  Manager or desi gnee will be responsible for forwarding the SAE form to 
the Case Management Group, Global Clinical Safety and Pharmacovigilance mailbo x 
The initial report will be followed up with more inform ation as relevant, or as requested by 
the GSK CH study  manager.
8.3.3 Sponsor’s Reporting Requirements to Regulatory Authorities and 
Ethics Committees
GSK has a legal responsibili ty to notify, as appropri ate, the local regulatory  authori ty and 
other regul atory authori ties about the safety  of a product under clinical invest igation.  Prom pt 
notification of SAEs by the invest igator to GSK is essent ial so that legal obligat ions and 
ethical responsibilit ies toward s the safet y of subjects are met.
GSK will com ply wi th country  specific regulatory requi rements rel ating to saf ety reporting to 
the regulatory  authori ty, IRB/EC and invest igators.
Page 43 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 43 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Invest igator safet y reports must be prepared for suspected unexpected serious adverse 
reacti ons (SUSAR) according to local regulatory  requirements and sponsor policy and 
forwarded to invest igators as necessary.
An investigator who receives an investigator safety report describing a SAE or other specific 
safet y inform ation eg, summ ary or listing of SAE) from the sponsor will review and then file 
it along with the Invest igator’s Brochure and will notify the IRB/IEC, if appropriate according 
to local requi rements.
8.4 Evaluating Adverse Events and Serious A dverse Events
8.4.1 Severity Assessmen t
The invest igator or designee will make an assessment of severi ty for each AE and SAE 
reported during the study  and will  assign it to one of the following categories:
Mild:  An event that i s easily tolerated by the subject, causing minimal discomfort and 
not interfering wit h every day act ivities.
Moderate:  An event that is sufficient ly discomforting to interfere with normal 
everyday act ivities
Severe:  An event that prevents normal everyday activit ies. 
Note: An AE that is assessed as severe will not be confused with an SAE. Severit y is a 
category utilized for rating the intensity of an event; and both AEs and SAEs can be assessed 
as severe. For example, a headache may be severe (interferes significantly with the subject's 
usual funct ion) but would not be classified as serious unless it met one of the criteria for 
SAEs, listed above. 
8.4.2 Causality Assessment
The causalit y assessment is one of the criteria used when determining regul atory  reporti ng 
requi rements. For each AE/SAE, the invest igator must docum ent inthe medical notes that 
he/she has reviewed the AE/SAE and has provi ded an assessment of causali ty.The 
investigator’s assessment of causali ty must be provided for all AEs (seri ous and non-serious); 
the invest igator must record the causal relat ionship in t he CRF , as appropri ate, and report such 
an assessment in accordance wit h the SAE reporting requirements if applicable.
A "reasonable possibilit y" of a  relationship conveys that there are facts, evidence, and/or 
argum ents to suggest a causal relationship, rather than a relationship cannot be ruled out.
Generally, the facts (evidence) or arguments to suggest a causal relati onship shoul d be 
provi ded.
The investigator will use clinical judgment to determine the relati onshi p and will also consul t 
the Invest igato r Brochure (IB), Safet y Statem ent and/or Product Informat ion, for marketed 
products, in the determinat ion of his/her assessment.  Alternative causes, such as underlying 
Page 44 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 44 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017disease (s), conco mitant therapy , other risk factors, and the temporal  relationship of the event 
to the study  product will  be consi dered and invest igated.
There m ay be si tuations when an SAE has occurred and the invest igator has minimal 
inform ation to include in the init ial report to GSK.  However, it is very important that the 
investigator always make an assessment of causality for every event prior to the initial 
transmission of the SAE data to GSK. The investigator may change his/her opinio n of 
causalit y in light of follow -up informat ionand send an SAE fo llow-up report wi th the updated 
causality assessment. 
8.5 Withdrawal Due to an Adverse Event and Serious Adverse 
Events
Withdrawal due to AEs shoul d be distinguished from withdrawal  due to other causes, 
according to the definit ion of AE noted earlier, and recorded on the appropri ate AE CRF
page. 
When a subject withdraws because of an SA E, the SAE must be reported in accordance with 
the reporting requirements defined below.
8.6 Pregnancy
8.6.1 Time Period for Collecting Pregnancy Information
Pregnancy inform ation will be collected on all pregnancies reported following administrati on 
of any invest igational product or washout product and until 5 days after the last treatment . 
8.6.2 Action to be Taken if Pregnancy Occurs
The invest igator will co llect pregnancy information on any subject who beco mes pregnant 
while participat ing in the study  after administrati on of  the invest igational product or washout 
product . The invest igator will record pregnancy information on the appropriate form and e -
mail itto the GSK CH Clinical Operat ions Safet y Reporting email box 
 within 2 4 hours of learning of the subject beco ming pregnant. The GSK 
CH Study  Manager or desi gnee will be responsible for forwarding the SAE form to the Case 
Management Group, Global Clinical Safet y and Pharm acovigilance mailbo x 
.
The subject will be fo llowed to determine the outcome of the pregnancy. Informat ion on the 
status of the mother and infant / neonate (including c oncomitant medicat ions taken by  the 
mother during the pregnancy) will be forwarded by the investigator to the GSK CH Clinical 
Operati ons Safet y Reporting email box and the GSK CH Study  Manager or desi gnee will 
forward thi s information to the Case Managemen t Group, Gl obal Clinical  Safety  and 
Pharmacovigilance group m ailbo x at GSK  Generally , follow-up will 
be no longer than 6 to 8 weeks fo llowing the est imated delivery date. Any termination o f the 
pregnancy will be reported.
Page 45 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 45 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017While pregnancy itself is not considered to be an AE, abnormal pregnancy  outcomes (eg, 
spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopi c pregnancy) are 
considered to be and should be recorded as an SAE.
Any female part icipant who becomes pregnant while participat ing will   discontinue study  
treatm ent or be wi thdrawn from  the study . 
8.7 Follow -up of A dverse Events and Serious A dverse Events
After the initial report, the invest igator is required to proactively follow up wi th each subject 
and provide further information on the subject’s condit ion.
All AEs/SAEs will be followed until resol ution, until the condi tion stabilizes, until the event 
is otherwi se explained, or until the subject is lost to fo llow-up.  
The invest igator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as may be indicated or as requested by GSK to elucidate as 
fully as possible the nature and/or causalit y of the AE or SAE. This may include additional 
laboratory tests or invest igations, histopathol ogical  examinat ions, or consultation with other 
healt h care professio nals.
New or updated informat ion will be recorded in the originally co mpleted CRF .
The invest igator will submi t any updated SAE data to GSK within 24 hours of receipt of the 
inform ation.
Invest igators are not obliged to actively seek AEs or SAEs in former subjects.  However, if 
the invest igator learns o f any SAE, including the death, at any  time after a subject has been 
discharged from  the study , and considers the event reasonably related to the investigat ional 
product or study  parti cipat ion, the invest igator will prompt ly notify  GSK by  emailing the 
inform ation to the GSK CH Clinical Operat ions Safet y Reporting email box 
. The GSK CH Study  Manager or desi gnee will be responsible for 
forwarding the informat ion to the Case Management Group, Global Clinical Safet y and 
Pharmacovigilance group m ailbo x at GSK .
The invest igator will submi t any updated SAE data to GSK within the designated reporting 
time frames.
8.8 Definition of and Procedure for Reporting Medical Device 
Incidents
Medical devic es are being provid ed by GSK CH for use in this study; the medical device in 
this study  is the washout manual toothbrush (Class I medical device).
8.8.1 Definition of an Incident
A medical device incident is any malfunct ion or deteri oration in the characteristics and/or 
perform ance of a device as well as any inadequacy in the labeling or th e instructions for use 
Page 46 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 46 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017which, directly or indirectly, might lead to or might have led to the death of a 
participant/user/other person or to a serious deterioration in his/her state of health.
Not all incidents lead to death or seri ous deteri oration in health. The nonoccurrence of such a 
resul t might have been due to other fortunate circumstances or to the intervention of health 
care personnel.
It is sufficient that:
An incident associated with a device happened and
The incident was such that, if it occurred again, might lead to death or a serious 
deteri oration in health.
A serious deterioration in state of health can include any  of the f ollowing:
Life-threatening illness
Perm anent impairment of body  functi on or perm anent dam age to body  structure
Condi tion necessitat ing medical or surgi cal intervent ion to prevent one of the above 
Fetal  distress, fetal death, or any  congeni tal abnormali ty or bi rth defects
Examples of incidents :
A participant, user, caregiver, or healthcare professio nal is injured as a result of a 
medical device failure or its misuse.
A participant’s study  treatm ent is interrupted or compromised by a medical device 
failure.
A misdiagnosis due to medical device failure leads to i nappropriate treatment.
A participant’s healt h deteriorates due to medical device failure.
8.8.2 Reporting of an Incidents and Malfunctions
All incidents must be reported to GSK within 24 hours (or sooner if possible) of 
the investigator or designee becoming awa re of the situation.
Any medical device incident occurring during the study  will be documented in the 
subject's medical records, in accordance with the invest igator's norm al clinical 
practi ce, and on the appropri ate Incident Report Form .  In addition, for incidents 
fulfilling the definit ion of an AE or an SAE, the appropri ate AE CRF page or SAE 
form will be com pleted and reported as per the AE and SAE reporting sections.
The Incident Report Form will be completed as thoroughly  as possible and signed by 
the invest igator before transmittal to GSK CH.  It is very important that the 
investigator describes any  corrective or rem edial acti ons taken to prevent recurrence of 
the incident.
Page 47 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 47 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017The completed Incident Report Form  should be emailed to the GSK CH Clinical 
Operations Safet y Reporting email box with the study  number and subject number in 
the subject line of the email as soon as possible, but not later than 24 hours after 
study  site personnel learn of the event. If there is an SAE, the completed SAE pages 
shoul d be sent together wi th this report f orm.  However, if a copy  of the SAE report i s 
sent wi th this form , this does not repl ace the procedure to report an SAE.  The ori ginal 
Incident Report Form will remain wit h the subject’s records.
The GSK CH Study  Manager shoul d be notified of the situation by  telephone or em ail.
Email the Incident Report Forms to:
The GSK CH Study  Manager or designee will be responsible for forwarding the 
Incide nt Report Form to the Case Management Group, Global Clinical Safet y and 
Pharmacovigilance group mailbox , responsible for the study 
and other GSK CH personnel as appropriate.
The initial report will be followed up with more informat ion as relevant, or as 
requested by  the GSK CH study  manager.
The invest igator will follow the following directi ons regarding the reporting of a device 
failure (malfunct ion):
Notify  GSK CH immediately (by following the proc ess described above) .
Schedule the subject to return to the site prompt ly to return the failed device.
Record any incidents on the CRF and Incident Report Form  following instructi ons 
given in the sect ion above.
Return the failed device to the sponsor as so on as possible, including documentation of 
the details of the failure 
8.8.3 Follow -up of Medical Device Incidents
All medical device incidents invo lving an AE will be fo llowed and reported in the 
same m anner as other AEs .This applies to all participants, inclu ding those who 
discontinue study  treatm ent or the study .
The invest igator is responsible for ensuring that follow -up includes any supplemental 
investigat ions as indicated to elucidate the nature and/or causalit y of the incident.
New or updated information will be recorded on the originally completed form with 
all changes signed and dated by  the invest igator.
8.8.4 Regulatory and Ethics Reporting Requirements for Incidents
In order to fulfill regulatory reporting obligat ions worldwide, the investigator is 
responsi ble for the detecti on and documentati on of events meet ing the definit ions of 
incident or malfunction that occur during the study with such devices. Medical device 
Page 48 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 48 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017incidents or malfunct ions of the device that resul t in an incident will be detected, 
docum ented, and reported during all periods of the study  in which the medical device 
is used. 
The invest igator will pro mptly report all incidents occurring with any medical device 
provi ded for use in the study  in order for the sponsor to fulfill the legal respons ibilit y 
to notify  appropri ate regul atory  authori ties and other entit ies about certain safet y 
inform ation relating to medical devices being used in clinical studies.
The invest igator, or responsible person according to local requirements (eg, the head 
of the medical institution), will comply with the applicable local regulatory 
requi rements rel ating to the reporting of incidents to the IRB/IEC.
9 DATA MANAGEMENT
As used in this protocol , the term  CRF shoul d be understood to refer to ei ther a paper form or 
an electroni c data record or both, depending on the data collection method used in this study . 
For this study  subject data will be entered into an electroni cCRF using a validated data 
system . 
9.1 Source Documents/ Data
The source docum ents, such as diary  cards, whic h contain the source of data recorded in the 
CRF shoul d be specified in Section 6. The CRF can be used as a source docum ent at the 
discreti on of  data management.
Each subject will be assigned and identified by a unique Screening Number. Any reference 
made to an individual subject within the study must be done using the unique Screening 
Number.
9.2 Case Report Form
A CRF is a printed, optical, or electroni c document designed to record all of the protocol 
requi red informat ion to be reported to the sponsor oneach trial subject. Refer to the 
appropriate CRO handbook and study -specific CRF specificat ions.
For each subject who has given informed consent/assent and has been screened, CRF must be 
completed and signed by the Principal Investi gator (or authori zed de signee) to certify that the 
data are complete and correct.  
Management of clinical data will be performed in accordance with Third Party  Biostatistics 
and Data Management vendor applicable standards and data cleaning procedures with 
oversi ght by GSK CH to ensure integrity of the data e.g., rem oving errors and inconsistencies 
in the data.
Page 49 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 49 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017In order to protect the privacy of subjects, no Personally Identifiable Informati on (PII) 
(including the subject's name or initials or full birth date) is to be recorded in the CRF or as 
part of the query  text.
All CRF pages shoul d be completed during a subject assessment when the CRF has been 
designated as the source.  Data that is sourced elsewhere shoul d be entered into the CRF in an 
agreed upon timeframe between the Inv estigator and Sponsor.  
GSK CH will obtain and retain all CRFs and associ ated study  data at the completion of the 
study . 
9.3 Data Handling
Docum entati on of all data management activit ies shoul d allow step-by-step retrospective 
assessment of data qualit y and study performance. 
Any changes or corrections to data will be performed in the Electroni c Data Capture (EDC) 
System , and it will include rationale for changes. The EDC system has an audit trail, which 
will provide a complete record of the changes and correcti ons endorsed by  the Invest igator.
Adverse events will be coded using MedDRA (Medi cal Dictionary for Regul atory  Activities) 
and conco mitant medications terms (if applicable) using an internal validated medication 
dictionary, GSKDrug.  
9.3.1 Queries
Prog rammed edi t checks will be generated autom atically , as the data is being entered into the 
system . Data Management will also run reports and list ings on the CRF data, in addit ion to the 
queri es already programmed and generated by the system , to raise manual queries as needed 
for site clarificat ion or correcti on. The Clinical Dictionary Devel opment and Management 
Group will raise queries as needed on safet y data to code the terms (Adverse Events and 
Drugs) appropriately . 
The study  monitor at the study  site will review the CRFs in accordance with the monitoring 
plan, and any queries will be generated in the EDC System  to the Invest igator or designee, 
enabling the errors to be addressed in parallel with Data Management review. The study 
monitor can also run reports and listings on the CRFs, to raise manual queries as needed for 
site clarificati on or correcti on.
9.4 Processing Patient Reported Outcomes
Patient reported outcom e (PRO) data may be collected from diary cards, questi onnai res,etc, 
and entered into the sponsor’s clinical data managem ent system  (DMS) .  In instances where 
the PRO data is entered into the DMS by GSK CH, the PROs will be anonymized as agreed 
and docum ented prior to study initiation. PROs that are source will be retained by the 
investigator and certified copies will be sent to GSK CH. 
Page 50 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 50 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017In order to protect the privacy of subjects, no Personally Identifiable Informati on (PII) 
(including the subject's name or initials or bi rth date) is to be recorded on all PRO’s that will 
be forwarded to GSK CH.
9.5 External Data 
External Data are subject data obtained externally to the CRF. These data are generated from 
laboratory instruments, com puters or other sources and then transcribed into a file and format 
agreed upon by GSK CH to identify the subject and time point referenced in the CRF and/or 
protocol . 
An agreed upon qualit y control process is performed against the transcribed data to the source 
to ensure the accuracy of the transcri ption. The transcribed data is transmitted in an agreed 
upon form at to GSK CH . 
Reconciliat ion will be performed between the transcribed data and the clinical database to 
ensure subject and time point referenced in the Clinical Database.
10 STATISTICAL CONSIDERATIONS AND DATA ANALYSES
The endpo ints of thi s study  are described below a nd in Sect ion 10.2 
Primary end point: 
%SMHR 
The extent of remineralization will be calculated as the % recovery  in SMH, which is 
calculated from the enamel indentati on length at baseline, after the first erosive challenge and 
after the in situ remineralizat ion phase after 4 hrs of intraoral phase. 
Secondary end point :
%RER 
This end point aims to test whether the formulations prevent senamel demineralizat ion after 
the 4 hours intra oral remineralizati on phase as per a second erosi on challenge. The %RER is 
calculated based on the indentati on length at baseline, after the first and the second erosive 
challenge after 4 hrs . 
EFU
EFU is assessed by the microdrill enamel biopsy , and its determined after4hours in situ
remineralizat ion period but before the second extra -oral erosive challenge. This measurement 
will provide with micrograms of fluoride per square cent imeter (µ g F/cm). 
Page 51 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 51 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Exploratory end point: 
%SMHR, %RER and EFU after 2 hours of intraoral  exposure will be evaluated as expl oratory 
end po int.  
The ARR measures acid resistance of the treated enamel after 2 and 4 hours intraoral phase . It 
is calculated based on the indentati on length after the second erosive challenge and the in situ
remineralizat ion phase ,andafter the first erosive challenge and baseline.
10.1 Sample Size Determination
A sufficient number of healthy subjects will be screened so that up to 66 subjects are
rando mized to participate in the study  to ensure 60evaluable subjects complete the entire 
study . With asample size of 60 subjects that complete the study , the study  will have 90% 
power to detect a difference in means of 5.0 in %SMHR at 4 hours , assuming a standard 
deviat ion of differences of 11.92 (estimated from GSK study  Z2560490, which was a study  of 
similar design ), using a pai red t-test wi th a 0.05 two -sided significance level.
A sample size of 60 subjects will be large enough to also detect a difference of 7.4 in RER 
with 80% power . 
A sufficient number of healt hy adult subjects will be selected from the Oral Health Research 
Institue’s IRB approved database of previous research studi es or from persons expressing 
interest in parti cipat ing in research, and screened for participat ion.
10.2 Statistical Methods and Analytical Plan
Addit ional details of the proposed statist ical analysis will be docum ented in the statistical 
analysis plan (SAP), which will be written following finalizat ion of the protocol  and prior to 
study  unblinding.
Treatment differences in the study  variables will be tested under the null hypothesis:
H0: there is no treatment difference versus the alternate hy pothesis
H1: there is a treatment difference.
10.2.1 Demographic and Baseline Characteristics
Descript ive statistics (number of subjects, mean, standard deviati on, median, minimum and 
maximum for continuous variables, and frequency and percentage for categori cal variables) 
will be provided for demographic, ethnici ty, baseline characteri stics, conco mitant 
medicat ions, medical history  and com pliance .
Page 52 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 52 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-201710.2.2 Primary Analysis(es) 
The primary efficacy  variable is %SMHR afte r 4 hours of remineralization.
Definition of primary variable:
% SMH recovery  = [(E1 -R)/(E1 -B)] * 100
B = indentati on length (μm ) of sound enamel at baseline
E1 = indentation length (μm) after first erosive challenge
R = ind entati on length (μm ) after in si tu reminerali zation
Per subject %SMHR will be determined from the %SMHR calculated for each specimen 
using five indentati ons measurements per specimen , averaged across the four specimens at 4 
hrs. Therefore, a single observa tion per treatment for each subject will be used in the 
statistical analyses. If a subject is missing an enamel specimen, the mean will be computed 
over the available ena mel specimens.
The ANOVA model will include fixed factors for study  period and treatm ent, and a random 
effect for subject. The baseline SMH and first demineralizat ion level will not be included in 
the model as covariate sas the samples will be preselected so that each sample has a 
measurement of 43 +/ -3 μm (at baseline, B) and 120 ± 20 μm ( after the fi rst erosive challenge, 
E1).
The primary  comparison of this study is the 1150 ppm fluori deexperimental dentifrice versus
the fluori de free placebo (0ppmF) and must be statist ically significant to meet the success 
criteria. The treatm ent difference and 95% CI will be presented for the primary comparison 
and allother%SMHR paired compar isons (classed as secondary and exploratory object ives).  
P-Values for these secondary and exploratory  comparisons will only be presented if the 
primary  com parison is stati stically significant.
The assumpt ions underlying the ANOVA will be examined, and if necessary , a suitable 
transformation or a non -parametric analysis will be performed (eg paired Wilco xon Si gn Rank 
test).
10.2.3 Secondary Analysis(es)
The se conda ry efficacy variables are:
i) % Rel ative Erosion Resistance (RER) after 4 hours intraoral phase.
ii) Enamel Fluoride Uptake (EFU) 4 hours intraoral phase.
Page 53 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 53 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Definition of secondary variables
% Rel ative Erosion Resistance = [(E1 -E2) / (E1 -B)] * 100
B= Indent ation length (μm ) of sound enamel at baseline
E1= Indentation length (μm) after first erosive challenge
E2= Indentation length (μm) after second erosive challenge
Per subject % RER will be determined for each specimen using five indentati ons
measurements per specimen , averaged across the four specimens at 4 hours. Therefore, a 
single observat ion per treatm ent for each subject will be used in the statisti cal analyses. If a 
subject is missing an enamel specimen, the mean will be com puted over the available enamel 
specimens.
Per subject EFU score will be calculated as follows: microdrill samples from each enamel 
specimen will be pooled and a value for fluoride content per enamel specimen determined. 
These values will be averaged across the four enamel specime nsfor each subject and time 
point to produce the subject -wise mean enamel fluori deuptake. 
Analysis of secondary variables
The same ANOVA model and testing procedure outlined for the primary variable will be 
conducted on the two secondary  variables.
The treatm ent difference and 95% CI will be presented for all  of the com parisons however the 
p-values for these secondary com parisons will only be presented if the primary com pariso n is 
statist ically significant.
The assumpt ions underlying the ANOVA will be examined, and if necessary , a suitable 
transformation or a non -parametric analysis will be performed (eg paired Wilco xon Si gn Rank 
test).
10.2.4 Safety Analysis(es)
All assessments of safety will be based on the safety  population, defined as all subjects who 
are rando mised and receive at least one dose of study  treatm ent during the study . Safety 
analyses will be performed according to the treatment that the subject received (using variable 
ATRT). All adverse events (AEs) will be reviewed by the Clinical Researc h Scient ist or
Designee pri
or to database lock and unblinding and will be coded using the Medical
Dictionary for Regul atory  Activities (MedDRA). During this review stage, AEs will be 
further categori zed as oral or non-oral. AEs will be listed and summarize d by treatm ent 
received. Serious AEs will also be listed. AEs will be regarded as treatment emergent if they 
Page 54 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 54 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017occur on or af ter the first treatm ent applicat ion at the baseline visit. The following AEs tables 
split by  treatm ent will be produced:
Listing of a ll AEs (including Non -treatm ent emergent AEs from all subjects)
Listing of all AEs for screened subjects
Treatment emergent AEs by Oral/Non -Oral Preferred Term  (PT)
Treatment emergent AEs by System Organ Class (SOC) and PT
Treatment emergent AEs by intensi ty and PT
Treatment emergent treatment related AEs by Oral/Non -Oral
Treatment emergent treatment related AEs by SOC
Listing of serious AEs (if there are none a null listing will be produced; ifthere are 
more than 5 treatm ent emergent serious AEs (SAEs) a table will beproduced instead 
by SOC and PT)
Non-serious treatm ent em ergent AEs by SOC and PT (only produced if there are m ore 
than 5 SAEs).
Listing of incidents (if there arenone a null list ing will be produced).
Further information related to safety also includes a table and listing of OST data.  The table 
will show changes in abnorm ality pre and post treatm ent.  A table of exposure not needed in 
this study  as it is a single use study .
10.2.5 Other Analysis(es)
Exploratory  efficacy variables are:
i) %SMHR a fter 2 hours intraoral phase
ii) % RER after 2 hours intraoral phase.
iii) EFU after 2 hours intraoral phase.
iv) ARR after 2 and 4 hours intraoral phase
Definition of exploratory variables
%SMHR asdefined above per primary  variable, and %RER and EFU as defined above per 
secondary  variables.
Page 55 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 55 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017The ARR will be calculated as fo llows:
ARR = 1- [ (E2 -R) / (E1 -B)]
B= Indentation length (μm) of sound enamel at baseline
R= Indentation length (μm) after in situ remineralization
E1= Indentation length (μm) after first erosive challenge
E2= Indentation length (μm) after second erosive challenge
Analysis of exploratory variables
For %SMHR, %RER and EFU variables the same ANOVA model and testing procedure 
outlined for the primary and secondary variables will be conducted on these exploratory 
variables. All pair-wise treatm ent comparisons will be estimated form the respect ive models 
for the variables. The treatm ent difference and 95% CI will be presented for all of the 
comparisons made however the p-values for these exploratory  comparisons will only be 
presented if the primary comparison is statist ically significant.
For ARR, summary  stati stic table by treatment and time po int will be provided.
10.2.6 Definition of Analysis Populations
All assessments of safety will be based on the safety  population, defined as all subjects who 
are rando mised and receive at least one dose of study  treatm ent during the study . Safety 
popul ation summaries will be presented by  treatm ent received.
The primary popul ation for efficacy assessment will be the intent-to-treat (ITT) populat ion, 
defined as all subjects who are rando mized, receive the study  treatm ent at least once and 
provi de at least one post-baseline (post treatm ent) assessment of efficacy. All ITT popul ation 
summaries and analyses will be presented by  treatment randomized.
10.2.7 Exclusion of Data from Analysis 
Exclusio n of any data from the analyses will be determined 
during a Blind Data Review 
Meet ing prior to database l ock. Any reasons for excl usion from an analysis popul ationwill be 
listed, if applicable.
Page 56 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 56 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017The per protocol  (PP) populat ion is defined as all subjects in the ITT populat ion who have at 
least one assessment of the primary endpo int efficacy considered unaffected by protocol 
violations.
PP analysis will be performed only on those data considered unaffected by protocol 
violations.
Efficacy analysis on the PP populati on will be performed only on the primary variable 
(%SMHR) only if there is more than 10% difference in the number of subjects per treatm ent
between PP and ITT populat ions. 
A decisio n on whether a PP analysis will be performed will be made prior to study  unblinding
10.2.8 Handling of Dropouts and Missing Data 
Subjects who withdraw from the study  early will be included in the study  analysis up to the 
point of withdrawal. Subjects who withdraw will not be replaced. No data will be imputed in 
the case of dropouts or missing data.
10.2.9 Interim Analysis
No interim analysis is planned for this study
11 STUDY GOVERNANCE CONSIDERATIONS
11.1 Quality Control 
In accordance with applica ble regulat ions including GCP, and GSK procedures, GSK or 
designee (i.e. third party  vendor) m onitors will contact the si te pri or to the start of the study  to 
review with the site staff the protocol , study  requirem ents, and their responsibilit ies to sati sfy 
regul atory , ethical , and GSK requi rements.
When reviewing data collection procedures, the discussi on will include ident ificat ion, 
agreem ent and documentati on of data items for which the CRF will serve as the source 
docum ent.
GSK or designee will mo nitor the study  and si te activi ty to verify  that the:
Data are authentic, accurate, and complete.
Safety and ri ghts of  subjects are being protected.
Study  is conducted in accordance with the currently approved protocol  and any other 
study  agreements, GCP, and al l applicable regulatory  requi rements.
The extent and nature of monitoring will be described in a written monitoring plan on file at 
GSK CH. The investigator (or designee) agrees to allow the monitor direct access to all 
relevant docum ents and agrees to co-operate with the monitor to ensure that any probl ems 
detected in the course of these monitoring visit s are resolved.
Page 57 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 57 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-201711.2 Quality Assurance
To ensure compliance with GCP and all applicable regulatory  requirements, GSK may 
conduct a qualit y assurance assessme nt and/or audit of the site records, and the regulatory 
agencies may conduct a regul atory  inspect ion at any time during or after completion of the 
study . 
In the event of an assessment, audi t or inspecti on, the invest igator (and inst itution) must agree 
to grant the advisor(s), auditor(s) and inspector(s) di rect access to all relevant docum ents and 
to allocate their time and the time of their staff to discuss the conduct of the study , any 
findings/relevant issues and to implement any corrective and/or preven tative actions to 
address any  findings/issues ident ified.
The invest igator(s) will notify GSK CH or its agents immediately of any regulatory  inspecti on 
notification in relation to the study . Furtherm ore, the invest igator will cooperate with GSK 
CH or its agents to prepare the study  site for the inspect ion and will allow GSK CH or its 
agent, whenever feasible, to be present during the inspect ion. The investigator will prom ptly 
apply copi es of  the inspection finding to GSK CH or i ts agent. Bef ore response sub missio n to 
the regul atory  authori ty, the investigator will provi de GSK CH or its agents with an 
opportunit y to revi ew and comment on responses to any  such findings. 
The sponsor will be available to help investigators prepare for an inspection.
11.3 Regulatory and Ethical Considerations
11.3.1 Institutional Review Board/ Ethics Committee 
It is the responsibilit y of the investigator to have prospective approval of the study protocol , 
protocol  amendments, informed consent documents, invest igator brochure/safet y statemen t 
(including any updates) and other relevant documents, e.g., recruit ment advert isements, if 
applicable, from the IRB/EC.  All correspondence with the IRB/EC shoul d be retained in the 
investigator file.  Copies of IRB/EC approvals shoul d be forwarded to GSK CH prior to the 
initiation of the study , and also when subsequent amendments to the protocol are made.
The only circumstance in which an amendment may be initiated prior to IRB/EC approval is 
where the change is necessary  to eliminate apparent immediate hazards to the subjects.  In that 
event, the invest igator must notify the IRB/EC and GSK CH in writing immediately after the 
implementation.
11.3.2 Ethical Conduct of the Study
The study  will be conducted in accordance with legal and regulatory  requirements, as well as 
the general  principles set forth in the Internati onal Ethical Guidelines for Biomedical 
Research Involving Human Subjects (Council for International Organizat ions of Medical 
Sciences 2002), guidelines for GCP (ICH 1996 and revisi on 2), and the Decla ration of 
Helsinki (World Medical Associat ion 2013). 
Page 58 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 58 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017In addit ion, the study  will be conducted in accordance wi th the protocol , the ICH guideline on 
GCP, and applicable local regulatory  requi rements and l aws.
11.3.3 Subject Information and Consent
All parties will ensure protecti on of subject personal data and will not include subject names 
or other ident ifiable data in any reports, publications, or other disclosures, except where 
requi red by laws. 
When study  data are compiled for transfer to GSK CH and other authorized parties, subject 
names, addresses, and other identifiable data will be replaced by numerical codes based on a 
numbering system provided by  GSK CH in order to de -ident ify study  subjects .  
The study  site will maintain a confident ial list of subjects who participated in the study , 
linking each subject’s numerical code to his or her actual ident ity.  In case of data transfer, 
GSK CH will maintain high standards of confident iality and protecti on of subjects’ personal 
data consistent with applicable priv acy laws.
The informed consent docum ents must be in compliance with ICH GCP, local regulatory 
requi rements, and l egal requirements, including applicable privacy  laws.
The informed consent docum ents used during the inform ed consent process must be reviewed 
and approved by the sponsor, approved by the IRB/EC before use, and available for 
inspection.
The invest igator must ensure that each study  subject, is fully inform ed about the nature and 
objectives of the study and possible risks associated with participat ion. 
The investigator, or a person designated by the invest igator, will obtain written informed 
consent from each subject before any study -specific activit y is performed.  The invest igator 
will retain the original o f each subject's signed informed consent document.
11.3.4 Subject Recruitment 
Advertisements approved by IRBs/ECs and investigator databases may be used as recruit ment 
procedures.   Use of ethics committee approved, generic, prescreening quest ionnaire to assess 
basic subject characterist ics to determin e general eligibilit y for this study  is allowed. This 
generic quest ionnaire may be used by sites as a phone script and/or to review internal 
databases to ident ify subjects.  
GSK CH will have an opportuni ty to review and approve the content of any study r ecrui tment 
materi als di rected to potenti al study  subjects before such materials are used. 
11.3.5 Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP 
Within a GSK CH a serious breach is defined as a breach likely to affect to a significant
degree the safety  and rights of  a subject or the reliabili ty and robustness of the data generated 
in GSK CH -sponsored human subject research studies. 
Page 59 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 59 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017In the event of any prohibit ion or restri ction imposed (i.e., clinical hold) by an applicable 
competent authori ty in any area of the world, or if the investigator is aware of any new 
inform ation that might influence the evaluat ion of the benefi ts and risks of  the invest igational 
product, GSK CH should be informed immediately. 
In addition, the invest igator will inform GSK CH immediately of any urgent safet y measures 
taken by the invest igator to protect the study  subjects against any immediate hazard, and of 
any serious breaches of this protocol or of ICH GCP that the invest igator becomes aware of.
11.4 Posting of Information on Publicly Available Clinical Trial 
Registers
Study  informat ion from this protocol will be posted on publicly available clinical trial 
registers before enro llment of subjects begins in accordance with applicable GSK processes.
11.5 Provision of St udy Results to Investigators
Where requi red by applicable regulatory  requirem ents, an investigator signatory will be 
ident ified for the approval of the clinical study  report.  The invest igator will be provided 
reasonable access to statistical tables, figur es, and relevant reports and will have the 
opportunit y to review the complete study  results at a GSK site or other mutually -agreeable 
location.
GSK will also provi de the invest igator with the full summary of the study  results.  The 
investigator is encourag ed to share the summary resul ts with the study  subjects, as 
appropriate.
The procedures and timing for public disclosure of the resul ts summary and for devel opment 
of a manuscri pt for publicat ion will be in accordance with GSK Policy.
A manuscript will be progressed for publicat ion in the scient ific literature if the resul ts 
provi de important sci entific or medical knowledge.
11.6 Records Retention
Following closure of the study , the investigator must maintain all site study  records (except 
for those requi red by local regulat ions to be maintained elsewhere), in a safe and secure 
location.  
The records (study / site master file) must be maintained to allow easy and timely retrieval, 
when needed (e.g., for a GSK audi t or regul atory inspect ion) and must be available for review 
in conjuncti on wi th assessment of the facilit y, supporti ng systems, and relevant site staff.
Where permi tted by local laws/regulations or institutional po licy, som e or all of these records 
can be maintained in a format other than hard copy  (e.g., microfiche, scanned, electronic); 
however, caution needs to be exercised before such act ion is taken. 
The invest igator must ensure that all reproducti ons are legible and are a true and accurate 
copy  of the original and meet accessibilit y and retrieval standards, including re-generat ing a 
Page 60 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 60 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017hard copy , if requi red.  Furtherm ore, the invest igator m ust ensure there is an acceptable back-
up of these reproducti ons and that an acceptable qualit y control process exists for making 
these reproductions.
The invest igator must assure that the subject’s anonymi ty will be maintained.  On CRFs or 
other documents submitted to GSK CH, subjects shoul d not be ident ified by their names or 
initials, but by an ident ificat ion code. The invest igator shoul d keep a separate log of subjects’ 
codes, names and addresses.  Docum ents not for submissio n to GSK CH, e.g. subjects’ 
written consent forms, should be maintained by the invest igator in strict confidence.
Records and docum ents, including signed ICF, pertaining to the conduct of this study  must be 
retained by the invest
igator for 25 years from the issue of the final Clinical Study Report 
(CSR)/ equivalent summary unless local regulat ions or institutional policies requi re a longer 
retenti on period. The minimum retenti on time will meet the strictest standard applicable to 
that site for the study , as dictated by any institutional requi rements or local laws or 
regul ations, GSK standards/procedures, and/or institut ional requirements.  
No study docum ent shoul d be destroyed without a  prior w ritten agreement between GSK CH 
and the investigator. The invest igator must notify GSK of any changes in the archival 
arrangements, including, but not limited to, archival at an off-site facility or transfer of 
ownership of the records in the event the inv estigator i s no l onger associ ated wi th the si te.
11.7 Conditions for Terminating the Study 
Prem ature terminat ion of this study  may occur because of a  regulatory  authori ty decision, 
change in opini on of the IRB/EC, or invest igational product safet y probl ems, orat the 
discreti on of GSK CH.  In addition, GSK CH retains the right to discont inue devel opment of 
the experimental dentifriceat any time. For multicenter studi es (if applicable), this can occur 
at one or more or at all sites.  
If a study  is prematurely  terminated, GSK CH will prom ptly notify the invest igator.  After 
notification, the invest igator must prom ptly contact all partici pating subjects and shoul d 
assure appropri ate therapy / follow-up for the subjects.  As directed by GSK CH, all study 
materi als must be collected and all CRF completed to the greatest extent possible. Where 
requi red by the applicable regulatory requi rements, GSK CH shoul d inform the regulatory 
authori ty(ies) and the invest igator should promptly  inform the IRB/EC and provi de the 
IRB/EC a detailed written explanation of the terminat ion or suspensio n. 
If the IRB/EC terminates or suspends i ts approval/favorable opinion of a tri al, the investi gator 
shoul d prom ptly notify the GSK CH and provide GSK CH wi th a detailed wri tten explanat ion 
of the terminat ion or suspensio n.
Upon completion or prem ature discont inuat ion of the study , the GSK CH monitor will 
conduct site closure activit ies with the invest igator or site staff, as appropriate, in accordance 
with applicable regulat ions including GC P, and GSK CH Standard Operating Procedures.
Page 61 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 61 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-201711.8 Definition of Study End/ End of Study 
TheEnd of Study  (EOS) is defined as the date of the last laboratory  testing rel ated to primary  
and secondary  endpoints, to be achieved no later than 8 months after the da te of the last 
subject last visit. 
12 REFERENCES
Attin T (2006). Methods for assessment of dental erosion , vol. 20. Karger Monographs in Oral 
Science.
Barlow AP, Sufi F, Mason SC (2009). Evaluation of different fluoridated dentifrice 
formulations using an in situ erosion remineralizat ion model. J Clin Dent 20:192-198.
Barti zek RD, Gerlach RW, Faller RV, Jacobs SA, Bollmer BW, Biesbrock AR (2001). 
Reduc tion in dental  caries wi th four concentrati ons of  sodium fluori de in a dentifrice: a meta -
analysis evaluat ion. J Clin Dent 12:57-62.
Brunelle JA, Carlos JP (1990). Recent trends in dental caries in U.S. children and the effect of 
water fl uoridation. J Dent Res 69 Spec No: 723
-727; discussio n 820 -723.
Chow LC (1990). Tooth -bound fluoride and dental caries. J Dent Res69 Spec No: 595-600; 
discussio n 634 -
596.
Cochrane NJ, Zero DT, Reyno lds EC (2012). Remineralizat ion models. Adv Dent Res24:
129-132.
Featherstone JD, Glena R, Shariati M, Shields CP (1990). Dependence of in vitro 
demineralizat ion of apatite and remineralizati on of dental enamel on fluori de concentrati on. J 
Dent Res 69 Spec No: 620
-625; discussio n 634 -626.
Fowl er C, Willso n R, Rees GD (2006). In vitro microhardness studi es on a new anti-erosi on 
desensit izing toothpaste. J Clin Dent 17:100-105.
Fowl er CE, Graci a L, Edwards MI, Willson R, Brown A, Rees GD (2009). Inhibit ion of 
enamel erosi on and prom otion of lesion rehardening by fluori de: a whi te light interferom etry 
and micro indentation study . 
J Clin Dent 20:178-185.
Page 62 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 62 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017 
 
 
 
GSK -Z3480664 GSK Clinical Study  (2013): Evaluati on of a Test Mouthwash and Dent ifrice 
Regimen in an In -Situ Model  of Dental  Erosi on.
GSK -Z3480664 GSK Clinical Study  (2013): Evaluati on of a Test Mouthwash and Dent ifrice 
Regimen in an In Situ Model of Dental Erosion.
GSK -Z6961385 GSK Clinical Study  (2013): A Placebo Controlled Study  to Evaluate the 
Effect iveness of Two Gel to Foam Toothpastes Using a Modified In situModel  of Dental 
Erosi on and Remineralizat ion.
Shellis RP, Ganss C, Ren Y, Zero DT, Lussi A (2011). Methodology and models in erosi on 
research: discussio n and conclusio ns. Caries Res 45 Suppl 1: 69-77.
Stephen KW (1993). Dent ifrices: recent clinical findings and implicat ions for use. Int Dent J
43:549-553.
Zero DT (1995). In situ caries models. Adv Dent Res 9:214-230; discussio n 231 - 214.
13 APPENDIX
Page 63 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 63 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
CCI
CCI
CCI
CCI
CCI
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-201713.1 ABBREVIATION
The fo llowing i s a list of abbreviat ions that m ay be used in the protocol.
Table 13-1 Abbreviation
Abbreviation Term
AE adverse ev ent
ANOVA analysis of variance
ARR Acid resistance ratio
CI confidence interval
CRF case report form
CRO contract research organization
CSR clinical study report
CRS clinical research scientist
DMS data management system
EC ethics committee
EDC electronic data capture
EFU Enamel fluoride uptake 
EudraCT European Clinical Trials Database
GCP Good Clinical Practice
gr grams
GSK CH GlaxoSmithKline Consumer Healthcare
hrs hours
IB investigator’s brochure
ICH International Conference on Harmonisation
ID identification
IRB institutional review board
ITT intention to treat
MedDRA medical Dictionary for Regulatory Activities
min minutes
mL milliliters
N/A not applicable
OHT oral hard tissue
OST oral soft tissue 
PI principal investigator
PII personally identifiable information
PP per protocol
PRO patient reported outcome
RER relative erosion resistance
PT preferred term
Page 64 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 64 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
Sodium fluoride and potassium nitrate
208166
Clinical Protocol, 08 Aug 2017
GlaxoSmi thKline Consumer Healthcare Confidential
Template Versi on Effect ive: 22 -Jun-2017Abbreviation Term
SAE serious adv erse ev ent
SAP statistical analysis plan
SD standard deviation
sec seconds
SMH surface micro hardness
SMHR surface micro hardness recov ery
SOC system organ class
SRSD single reference study document
US United States
µg micrograms 
Page 65 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 65 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
 
 
SIGNATURE PAGE 
 
   
Date  Signed By
 
Justification    
 
 
Date  Signed By
 
Justification    
 
 
Date  Signed By
 
Justification     
 
Date  Signed By
  
Justification     
 
Date  Signed By
  
Justification    
 
 
Date  Signed By
  
Justification    
 
 
07-Nov-2017 10:31:10
Approved
Biostatistics Approval
06-Nov-2017 11:39:27
Clinical Operations Approval
208166_Clinical Protocol.docx
06-Nov-2017 11:17:47
Page 66 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
07-Nov-2017 10:31:16
208166_Clinical Protocol.docx
eldo_controlled
3.0; Effective; CURRENT
Auto Issue
090032d580db7db9Page 66 of 66
 Document Name   
Type  Version  Document Identifier  Effective Date  
    
Reason For Issue   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
gsk-208166-protocol-redact.pdf
eldo_controlled
0.1; CURRENT; Most-Recent; In Review
090032d58126e10f
PPD
PPD
PPD